Podcasts about Cold Spring Harbor Laboratory

Episode 051 | Greg Maguire, PhD is the Co-Founder of the SRM Living Foundry at UCSD in San Diego and the Co-Founder & Chief Scientific Officer of NeoGenesis, a wonderful company I talk with my patients about all the time. If you haven't yet listed to episode 047 featuring Christine Preston, that one pairs delightfully with my conversation with Dr. Maguire.Awarded a prestigious Fulbright-Fogarty Fellowship from the National Institutes of Health, Dr. Maguire managed his NIH funded laboratory at UCSD studying tissue degeneration and regeneration, and the role of stem cell released molecules (SRM) through paracrine and autocrine actions to maintain, repair, and regenerate human tissues. His NIH funded studies of systems biology and reverse engineering at UC Berkeley and stem cell biology at UC San Diego led to the development of adult stem cell-based S2RM® technology for the development of therapeutics and medical procedures.Dr. Maguire pursued his graduate training at the University of California, Berkeley, University of Houston, University of Texas, The Marine Biological Labs, Woods Hole, MA, and Cold Spring Harbor Laboratory, NY. He is a former professor of neuroscience and ophthalmology at the University of California, San Diego School of Medicine, a visiting associate professor of physiology at Keio University School of Medicine in Tokyo, Japan, visiting assistant professor of molecular neurobiology at the University of Washington, and a visiting scientist at Massachusetts General Hospital (MGH), at Harvard University.Dr. Maguire has over 100 publications and is currently working on his book entitled, “Spontaneous Stem Cell Healing”.The Above & Beyond Dermatology podcast is grateful to NeoGenesis for the great work they do and for their generous support of this episode. If you're a skin care professional and would like to learn more about helping your customers with NeoGenesis, click here to learn more. If you'd like to learn directly from the NeoGenesis team, text me at 715-391-9774 and I'll be happy to make a warm introduction.Connect with and learn from Greg Maguire & NeoGenesisLearn & Shop NeoGenesisDr. Maguire's Skin Care BlogNeoGenesis Wholesale Partnership for Medical ProfessionalsMore from Dr. Lewellis and Above & Beyond DermatologyNeed a dermatologist? Fill out this short interest form, text or call me at 715-391-9774, or email me at drlewellis@aboveandbeyondderm.com if you'd like to have a no obligation discovery call. I offer in-office visits, house calls, and virtual care in Wisconsin and virtual care in Illinois, Nebraska, and Colorado.Have an idea for a guest or want to be on the show yourself? Send me a text or email, and we'll see if it's a good fit.

On Easter Sunday 1996, a police officer comes across a car containing pieces of a dismembered body. The police catch the killer fairly quickly, but questions remain. Are there any more victims? And is there another killer at large?Sources:“Cold Spring Harbor Laboratory Honors the Memory of Yasha Gluzman, Ph.D. | Cold Spring Harbor Laboratory.” Cold Spring Harbor Laboratory, https://www.facebook.com/cshlnews, https://www.cshl.edu/giving-news/cold-spring-harbor-laboratory-honors-the-memory-of-yasha-gluzman-ph-d/. Accessed 27 Mar. 2025.Cutler, Nancy. “Rita Gluzman, Who Murdered Scientist Husband, Released from Prison.” The Journal News, Rockland/Westchester Journal News, 29 July 2020, https://www.lohud.com/story/news/local/rockland/2020/07/29/rita-gluzman-murdered-husband-released-prison/5540176002/.Hays, Tim. Severed Relations. Pinnacle Books, 1998.Rozier, Alex. “Woman Who Killed Husband with Ax Released from Fort Worth Prison | Khou.Com.” Khou.Com, KHOU, 11AD, https://www.khou.com/article/news/local/rita-gluzman-killed-husband-fmc-carswell-fort-worth-compassionate-release/287-97c2e730-6ac3-4b09-b0cf-024b0a48ef23.Smith, Benjamin H. “Rita Gluzman Sentenced For Killing Husband With Ax | Crime News.” Oxygen, Oxygen, 6 July 2018, https://www.oxygen.com/snapped/crime-time/woman-sentenced-to-life-in-prison-for-axing-husband-to-death-after-he-met-younger.Snapped. 2024.“United States v. Gluzman, 7:96-Cr-323 (LJL) | Casetext Search + Citator.” CoCounsel: One GenAI Assistant for Professionals | Thomson Reuters, https://casetext.com/case/united-states-v-gluzman. Accessed 23 Mar. 2025.“Yakov Gluzman (1948-1996) - Find a Grave Memorial.” Find a Grave - Millions of Cemetery Records, https://www.findagrave.com/memorial/191458609/yakov-gluzman. Accessed 23 Mar. 2025.This Week's Episode is Brought To You By:Shopify - The Platform Commerce is Built On - $1 per month trial https://shopify.com/lovemurderHiya Health - Essential Super Nutrients for Kids - https://hiyahealth.com/LOVEMURDER for 50% off your first orderBetterHelp - Convenient and affordable online therapy and counseling - https://betterhelp.com/lovemurder for 10% off your first monthSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

About the Guest:Meet Dr. Bruce Stillman, president and CEO of Cold Spring Harbor Laboratory, one of the oldest and most distinguished scientific and research facilities on the planet. Growing up, Bruce knew that medicine and science were in his future—he was already volunteering in hospitals at the age of fifteen. But little did he suspect that his first gig out of medical school would prove to be his entire career. “I was thirty-eight at the time,” he says. “And I got plucked out of the faculty here to become assistant director and, ultimately, director…I had no experience in running anything. But I knew the culture of the lab, the organization, and I think that was the most important thing that I've carried forward.” This knowledge informed his leadership approach, which ultimately led both the organization and its faculty and staff to flourish under his direction. Learn more about Bruce and his amazing career in this episode of the Take Command podcast.What You Will Learn:Lessons in conflict resolution and negotiationsStories of the ups and downs of being a Nobel laureateStrategies for bringing workers together under a single missionInsights into why having a big question to answer still requires flexibility in how you approach itJoin us for this incredible episode, where you'll learn everything you want to know about fostering an environment that supports mentorship and risk-taking. Bruce is here to share his knowledge. Don't hesitate to dive into his wisdom to make your own organization even better. Listen to the Take Command podcast today!  Please rate and review this Episode!We'd love to hear from you! Leaving a review helps us ensure we deliver content that resonates with you. Your feedback can inspire others to join our Take Command: A Dale Carnegie Podcast community & benefit from the leadership insights we share.

Support the show to get full episodes and join the Discord community. The Transmitter is an online publication that aims to deliver useful information, insights and tools to build bridges across neuroscience and advance research. Visit thetransmitter.org to explore the latest neuroscience news and perspectives, written by journalists and scientists. Read more about our partnership. Sign up for the “Brain Inspired” email alerts to be notified every time a new “Brain Inspired” episode is released: https://www.thetransmitter.org/newsletters/ To explore more neuroscience news and perspectives, visit thetransmitter.org. Tony Zador runs the Zador lab at Cold Spring Harbor Laboratory. You've heard him on Brain Inspired a few times in the past, most recently in a panel discussion I moderated at this past COSYNE conference - a conference Tony co-founded 20 years ago. As you'll hear, Tony's current and past interests and research endeavors are of a wide variety, but today we focus mostly on his thoughts on NeuroAI. We're in a huge AI hype cycle right now, for good reason, and there's a lot of talk in the neuroscience world about whether neuroscience has anything of value to provide AI engineers - and how much value, if any, neuroscience has provided in the past. Tony is team neuroscience. You'll hear him discuss why in this episode, especially when it comes to ways in which development and evolution might inspire better data efficiency, looking to animals in general to understand how they coordinate numerous objective functions to achieve their intelligent behaviors - something Tony calls alignment - and using spikes in AI models to increase energy efficiency. Zador Lab Twitter: @TonyZador Previous episodes: BI 187: COSYNE 2024 Neuro-AI Panel. BI 125 Doris Tsao, Tony Zador, Blake Richards: NAISys BI 034 Tony Zador: How DNA and Evolution Can Inform AI Related papers Catalyzing next-generation Artificial Intelligence through NeuroAI. Encoding innate ability through a genomic bottleneck. Essays NeuroAI: A field born from the symbiosis between neuroscience, AI. What the brain can teach artificial neural networks. Read the transcript. 0:00 - Intro 3:28 - "Neuro-AI" 12:48 - Visual cognition history 18:24 - Information theory in neuroscience 20:47 - Necessary steps for progress 24:34 - Neuro-AI models and cognition 35:47 - Animals for inspiring AI 41:48 - What we want AI to do 46:01 - Development and AI 59:03 - Robots 1:25:10 - Catalyzing the next generation of AI

Long Island has played a prominent role in scientific research and in engineering. It is the home of the Brookhaven National Laboratory in nuclear physics and Department of Energy research. Long Island is also home to the Cold Spring Harbor Laboratory, which was directed for 35 years by James D. Watson (who, along with Francis Crick and Rosalind Franklin, discovered the double helix structure of DNA). Companies such as Sperry Corporation, Computer Associates (headquartered in Islandia), Zebra Technologies (now occupying the former headquarters of Symbol Technologies, and a former Grumman plant in Holtsville), have made Long Island a center for the computer industry. Stony Brook University and New York Institute of Technology conduct advanced medical and technological research. PICTURE: By AdmOxalate - Own work, CC BY 3.0, https://commons.wikimedia.org/w/index.php?curid=7711855

Long Island is a populous island east of Manhattan in southeastern New York state, constituting a significant share of the New York metropolitan area in both population and land area. The island extends from New York Harbor 118 miles (190 km) eastward into the North Atlantic Ocean with a maximum north–south width of 23 miles (37 km).[2][3] With a land area of 1,401 square miles (3,630 km2), it is the largest island in the contiguous United States.[4] Long Island is divided among four counties, with Kings (Brooklyn), Queens, and Nassau counties occupying its western third and Suffolk County its eastern two-thirds. Long Island may refer both to the main island and the surrounding outer barrier islands. To its west, Long Island is separated from Manhattan and the Bronx by the East River tidal estuary. North of the island is Long Island Sound, across which lie Westchester County, New York, and the state of Connecticut. Across the Block Island Sound to the northeast is the state of Rhode Island. Block Island, which is part of Rhode Island, and numerous smaller islands extend farther into the Atlantic Ocean. To the extreme southwest, Long Island, at Brooklyn, is separated from Staten Island and the state of New Jersey by Upper New York Bay, The Narrows, and Lower New York Bay. With a population of 8,063,232 residents as of the 2020 U.S. census, Long Island constitutes 40% of New York state's entire population.[5][6][7][8][9] Long Island is the most populous island in any U.S. state or territory, the third-most populous island in the Americas after Hispaniola and Cuba, and the 18th-most populous island in the world ahead of Ireland, Jamaica, and Hokkaidō. Its population density is 5,859.5 inhabitants per square mile (2,262.4/km2). Long Island is culturally and ethnically diverse, featuring some of the wealthiest and most expensive neighborhoods in the world near the shorelines, as well as working-class areas in all four counties. As of 2022, Kings, Queens, Nassau, and Suffolk counties collectively had a gross domestic product of approximately $500 billion.[10] Median household income on the island significantly exceeds $100,000, and the median home price is approximately $600,000, with Nassau County approximating $700,000. Among residents over the age of 25, 42.6% hold a college degree or higher educational degree.[11] Unemployment on Long Island stays consistently below 4%. Biotechnology companies, engineering, and scientific research play a significant role in Long Island's economy,[12] including research facilities at Brookhaven National Laboratory, Cold Spring Harbor Laboratory, Stony Brook University, New York Institute of Technology, Plum Island Animal Disease Center, the New York University Tandon School of Engineering, the Zucker School of Medicine, and the Feinstein Institutes for Medical Research. As a hub of commercial aviation, Long Island is home to two of the nation's and New York metropolitan area's busiest airports, JFK International Airport and LaGuardia Airport.[a] Also located on Long Island are Long Island MacArthur Airport and two major air traffic control radar facilities, New York TRACON and New York ARTCC. Long Island has nine major bridges and thirteen navigable tunnels, which connect Brooklyn and Queens to the three other boroughs of New York City. Ferries connect Suffolk County northward across Long Island Sound to Connecticut. Long Island Rail Road is the busiest commuter railroad in North America and operates continuously.[13]

*The award lecture and its accompanying slides are also available to watch here: https://youtu.be/AmP_8FG0dDU. The Earl and Thressa Stadtman Distinguished Scientist Award is awarded to a distinguished scientist for their outstanding achievement in basic research in the fields encompassed by the ASBMB. Bruce Stillman is president and chief executive officer of Cold Spring Harbor Laboratory. Stillman's lab studies the process by which DNA is copied within cells before they divide. Learn more: https://www.asbmb.org/asbmb-today/people/081623/asbmb-names-2024-award-winners.

Today we're diving into some groundbreaking research that could potentially change the game when it comes to aging. Our spotlight is on a recent study published in Nature Aging by Cold Spring Harbor Laboratory, and it's all about using a "living" drug called chimeric antigen receptor(CAR) T Cells to tackle those pesky senescent cells. But before we get into the nitty-gritty, let's break it down for you in simple terms. Imagine your body as a city and senescent cells are like those old, rundown buildings that just refuse to budge. They don't function properly, and worse, they release signals that can negatively affect the surrounding healthy cells. These cells are dysfunctional and shoot out signals that wreak havoc on their healthy neighbors. Now, the researchers at CSHL is proposing a superhero-like solution: CAR T Cells.

Andreas Grill, President and CEO of DepYmed, discusses protein tyrosine phosphatase-targeted drugs, a new class of drugs. With a focus on the specific enzyme PTP1B, DepYmed discovered orally bioavailable molecules that inhibit PTP1B, targeting the signal transaction pathway. They are initially testing to treat Rett syndrome, a rare disease with no current therapy while exploring the use of PTP1B inhibitors to treat inflammatory diseases, cancer, diabetes, and neurological diseases.   Andreas elaborates, "In DepYmed, we're focused on a specific enzyme. It's PTP1B. It's part of a family of enzymes called protein tyrosine phosphatases, and, in particular, we're looking at PTP1B. It's a metabolic regulatory enzyme that regulates signal transduction between cells and how cells communicate with each other. It's been worked on in the '90s and early 2000s. A couple of companies were working on the target, and they failed in the target, mainly because they couldn't create an orally bioavailable compound that would inhibit the PTP1B enzyme itself." "So that was one of the holy grails that we were able to find, where we were able to discover molecules that were orally bioavailable and would inhibit PTP1B. It was a game-changer when it came to the therapeutics around the target of PTP1B. Much of this work came out of Dr. Nicholas Tonks' laboratory out of Cold Spring Harbor Laboratory. We are in close collaboration with Nick and his team at Cold Spring Harbor, developing this new area of PTP1B inhibitors targeting the signal transaction pathway." #DepYmed #RettSyndrome #DPM1003 #PTP1B #Phosphatases #PhosphatasesInhibitors #RareDisease DepYmed.com Download the transcript here

Andreas Grill, President and CEO of DepYmed, discusses protein tyrosine phosphatase-targeted drugs, a new class of drugs. With a focus on the specific enzyme PTP1B, DepYmed discovered orally bioavailable molecules that inhibit PTP1B, targeting the signal transaction pathway. They are initially testing to treat Rett syndrome, a rare disease with no current therapy while exploring the use of PTP1B inhibitors to treat inflammatory diseases, cancer, diabetes, and neurological diseases.   Andreas elaborates, "In DepYmed, we're focused on a specific enzyme. It's PTP1B. It's part of a family of enzymes called protein tyrosine phosphatases, and, in particular, we're looking at PTP1B. It's a metabolic regulatory enzyme that regulates signal transduction between cells and how cells communicate with each other. It's been worked on in the '90s and early 2000s. A couple of companies were working on the target, and they failed in the target, mainly because they couldn't create an orally bioavailable compound that would inhibit the PTP1B enzyme itself." "So that was one of the holy grails that we were able to find, where we were able to discover molecules that were orally bioavailable and would inhibit PTP1B. It was a game-changer when it came to the therapeutics around the target of PTP1B. Much of this work came out of Dr. Nicholas Tonks' laboratory out of Cold Spring Harbor Laboratory. We are in close collaboration with Nick and his team at Cold Spring Harbor, developing this new area of PTP1B inhibitors targeting the signal transaction pathway." #DepYmed #RettSyndrome #DPM1003 #PTP1B #Phosphatases #PhosphatasesInhibitors #RareDisease DepYmed.com Listen to the podcast here

The fourth Season of the National Institute of Neurological Disorders and Stroke's Building Up the Nerve podcast, where we discuss the unwritten rules, or “hidden curriculum,” of scientific research at every career stage. We know that navigating your career can be daunting, but we're here to help—it's our job!In episode 7, we talk about applying for a faculty position, including preparing your application, negotiating, and the accepting or re-applying process. Featuring Kimberly S Williams, Assistant Professor, Spelman College; Lucas Cheadle, Assistant Professor, Cold Spring Harbor Laboratory; and Erin Stephenson, Assistant Professor, Midwestern University.ResourcesNIH Research Training Initiative for Student Enhancement (RISE) Program (R25): https://nigms.nih.gov/training/RISE/Pages/default.aspx NIH Institutional Research and Academic Career Development Awards (IRACDA) (K12): https://nigms.nih.gov/training/careerdev/Pages/TWDInstRes.aspxAnnual Biomedical Research Conference for Minoritized Scientists (ABRCMS): https://abrcms.org/ Future PI Slack community: https://futurepislack.wordpress.com/ Neuroscience Development for Advancing the Careers of a Diverse Research Workforce (R25) Programs: https://www.ninds.nih.gov/funding/training-career-development/choose-award-career-stage-eligibility/diversity-awards/nih-neuroscience-development-advancing-careers-diverse-research-workforce-r25-faqs/neuroscience-development-advancing-careers-diverse-research-workforce-r25 BRAINS (R25): Broadening the Representation of Academic Investigators in NeuroSciences - A national program to increase the advancement of neuroscience researchers from diverse backgrounds: https://brains.uw.edu/ Transcript available at http://ninds.buzzsprout.com/.

Early geneticists were convinced they could use genetics to reshape society to their ideals and believed that the human race could be improved through selective breeding. An early seat for eugenics in the U.S. was Cold Spring Harbor Laboratory on Long Island. As the lab's influence began to extend to the halls of Congress, the Supreme Court, and internationally, Cold Spring Harbor became known as the eugenics capital of the world.

In this final episode of Season three, Siobhan Kiernan from the class of 2021 speaks with Sean O'Connor from the class of 1992. As a fundraiser and member of the Holy Cross Annual Fund Team, Siobhan talks with Sean about his accomplished career in fundraising. Today, he continues to make a difference as the Chief Development Officer at the National Audubon Society. Their conversation gives you a behind-the-scenes look at what it takes to support the nonprofit organizations that we love. The Holy Cross mission of serving others is central to the work that they do. As people foreign with others, their careers modeled the idea of doing well while doing good. Interview originally recorded in August 2022. --- Sean: When I'm being reflective of the relationship between the effort and the work that I've applied my daily profession to the outcome, it completely aligns with my worldview of actually helping other people and helping organizations and helping the world. Whether it's through art, or healthcare or science or human rights or conservation, I feel pretty good about that. Maura: Welcome to Mission Driven, where we speak with alumni who are leveraging their Holy Cross education to make a meaningful difference in the world around them. I'm your host, Maura Sweeney, from the class of 2007, Director of Alumni Career Development at Holy Cross. I'm delighted to welcome you to today's show. In this final episode of Season three, Siobhan Kiernan from the class of 2021 speaks with Sean O'Connor from the class of 1992. As a fundraiser and member of the Holy Cross Annual Fund Team, Siobhan talks with Sean about his accomplished career in fundraising. After a year in the Jesuit Volunteer Corps, Sean accepted a role raising funds for a small Catholic school on the Lower East Side of Manhattan. Thanks to the support and encouragement of some Holy Cross alumni, he accepted a position with CCS fundraising, which brought his fundraising overseas and greatly expanded the scope of his work. Today, he continues to make a difference as the Chief Development Officer at the National Audubon Society. Their conversation gives you a behind-the-scenes look at what it takes to support the nonprofit organizations that we love. The Holy Cross mission of serving others is central to the work that they do. As people foreign with others, their careers modeled the idea of doing well while doing good. Siobhan: Hello everyone. My name is Siobhan Kiernan and I am a 2021 Holy Cross grad, and current member of the Holy Cross Fund Team. And I'm joined here with Sean O'Connor. Hello, how are you? Sean: Hi Siobhan. Good to see you again. Siobhan: Yeah, you too. Where are you zooming from? Sean: I'm zooming from Goldens Bridge, New York, which is Northern Westchester County near Bedford and North Salem. Siobhan: Nice. Oh my gosh. I'm zooming from New York City, so... Sean: Oh wow. Whereabouts? Siobhan: In like little... I'm on the Upper East Side right now. It's where I grew up. Sean: Oh, that's right. I grew... For a while. I lived on 83rd and third when I did all this. Siobhan: Oh yes, we talked about this. Sean: Yeah, right. Siobhan: Oh, that's awesome. Are you from New York? Sean: No, I actually grew up in Worcester, Massachusetts where there's a school called Holy Cross, is there I think. And I in that way was born at St. Vincent Hospital and then grew up really in Holden, Massachusetts, which is just north of Worcester. And I went to Wachusett Regional High School. And I know your next question is why I don't have an accent, but for some reason I dropped the Worcester accent. When I went to Holy Cross, actually, ironically, I think my accent started to go away. Siobhan: They ironed it out of you. Sean: They must have ironed it out of me, yes. I could put on the Worcester accent, but only under severe pressure. Siobhan: That's so funny. I've been told that I don't have a New York accent either. Sean: No, you don't. Siobhan: So I guess there's something about Holy Cross and taking out accents. So you kind of really just started this, I guess, but why Holy Cross? I mean, I know you're from Worcester, but some people I know probably wouldn't have wanted to go to a school in their hometown. So why did you stay, and what about Holy Cross made you want to go there? Sean: It is a family school. For me, my grandfather was class of '31 and my father was class of '66. My uncle was class of '62. I think even have one of my other father's relatives went there. And so I always had heard about Holy Cross. And I lived on campus, I didn't commute even though I was about 10 miles away from Worcester, or from home rather. But it was obviously one of the most important decisions I made as a young person. And then probably, in truth, is probably the best school I got into when I was applying for colleges. That was another part as well. Siobhan: No, but that worked out. The one thing I love about Holy Cross is that you can feel very much away even if you are local. Sean: Right. Siobhan: I have friends who lived off campus and I remember I always lived on campus and my thought process was, you have your whole life to live outside the gates of Mt. St. James. Why would you want to go now? Sean: Right, for sure. But I enjoyed it. It was great. Siobhan: Yeah. So what was your time on campus? What did you do? What did you major in? What activities did you like to do? Sean: I was a history major, and I took my academics semi-seriously, I think. I'm a lifelong reader and I probably am still interested in history and read a lot of William Durant history surveys when I'm on the plane on a tarmac or something like that. So I still enjoy learning, but I spent a lot of time on extracurricular activities. I didn't play sports, and maybe once in a while would play a soccer pickup game if one existed. But I was involved in the radio station, I was the station manager for a year. Siobhan: Oh cool. Sean: And a DJ. And then I was involved, I think in one of the campus activity boards, I think my senior year. Is it called SS or something? I'm trying to remember then what the acronym was. Siobhan: Or is it CAB? I mean, today I think it's probably the equivalent. Sean: Something like that. I would put on concerts at Hogan. I did one concert. I think I almost got kicked off campus because I did not go through the proper channels of getting permits and things like that. So I learned a lot at college about doing things like that. We had a band called The Mighty, Mighty Boss Tones playing in the basement, which was a fun, legendary show. And then when I was at the station, radio station, we did a kind of benefit concert for the Worcester Coalition for the Homeless in Worcester. There was a band named Fugazi that we brought up to Worcester and did a show, which is fun. So we did some fun stuff connecting Worcester where I grew up to Holy Cross. I was also a resident assistant in the Mulledy basement. So yeah, it was a fun four years. Siobhan: Wow. So you mentioned you were a history major. I'm always curious, because I did economics, why history? And did you have a favorite class? Sean: I kind of go back and forth between really US history and European history or world history. And I did take an African history class, which is pretty influential. Professor David O'Brien was my advisor and he's kind of a labor and Catholic historian. And I still am interested in labor history. I can get really geeky I suppose, about history. I just really do enjoy it in terms of understanding patterns and issues and big issues that we're facing now as a country, and what are the historical analogs, and what has happened in the past that informs where you are right now. And all my family were English majors or our English majors. I think my daughter is an English, is going to become an English major, not a history major. My son was a poly sci major at Bucknell and a film major. But history is, I just enjoy it. And I go back and forth. I probably read more non-US history these days, but it's an escapism too for me. Dealing with everything else, it's kind of fun to read about the Age of Enlightenment or something like that, and just learn about different thinkers and different parts of history that you weren't aware of. And then if you get really excited, you can go deep on those things and get really geeky. Siobhan: I took one history class in Holy Cross, and I found that I almost felt like an investigator, like a detective, which as an economics major it is... That's a different way of thinking. So actually I have a lot of respect for the history department. Cause you very much have to tell a story, and really unpack documents and things. And I think that's... Sean: Yeah, for sure. Siobhan: And you mentioned your professor. I always love to hear about, because the school is so small and the community is so great. Is there anyone that comes to mind who had a meaningful impact on you at Hogan? Sean: Academically, David Chu, who is my accounting professor, and I just didn't do as well in accounting, but that taught me a lot about the importance of studying, actually. There was a professor Whall when I took my early survey class in history, which kind of awakened me to academic writing in a different way. And I lifeguarded at the pool, so got to hang out with the late Barry Parenteau who just passed away. And that was fun times there. And then some of the student life people, I think Dean Simon, I'm trying to remember his name, but he was the one that I worked with a little bit in my senior year. He was the Student Life Dean, if I remember correctly, out of Hogan. And then actually career advisors towards the end. I think one of the more influential people in my career, if we segue into that section, is this John Winters, who is there as a career advisor who really got me on the pathway of where I am right now. Siobhan: Oh, fabulous. Actually, that was a great segue. That was actually my next question was going to be, could you just take me through from commencement to where you are? Sean: Sure. Siobhan: Your journey. I did look into your bio a little bit and you had a very vast career so far, but I want to hear about it from you, your whole journey. Sean: So when I got out of school, I remember second semester, senior year, gosh knows what you're going to do. But I think I interviewed, think at some advertising agency, Leo Burnett, that has historically hired Holy Cross grads and did not get the interview. But I was able to go to Chicago for that all day interview, which was kind of fun. Get to stay in the fancy hotel for the first time. And then when I got out of school I ended up going to Jesuit Volunteer Corps. So I did the Jesuit Volunteer Corps in the northwest and was stationed, or placed, I guess is the language in Auburn, Washington, which is between Seattle and Tacoma. And my placement, or my job, the volunteer job was working at a residential youth shelter for physically and sexually abused kids. And I was doing that for a year. And so my job was to take to care of them, drive them to school, make them dinner, take them on field trips, and then talk to them. And then, learning what it meant to be a social worker and would write about my day and my interactions to help the therapists and the psychologists who are helping them connect the dots about what issues they were facing. They were typically there for a couple of weeks. It was transitional short term, before they might have been between foster placements or they might have been just removed from the home. And the state was trying to figure out what to do with them. So it was a very eye-opening experience, making $20 a week living in a community in the Jesuit Volunteer Corps. But that moment I was actually really interested in understanding how nonprofits were financed. I was like, all right, so how did they actually get the money to do the work? How does it actually work? So I was able to understand a little bit about the particular organization I was volunteering at. It was called Auburn Youth Resources. And they would receive a lot of money from the King County, which is the local county outside of Seattle. But the philanthropy piece, that people would give them money was relatively small. And anyways, it was, it's an opportunity for me to think about that. I wanted to do good but also do well. And I think a lot of this has to do with Holy Cross, but also that my parents or both teachers. My brother's a teacher, my sister's a teacher, my other sister who went to Holy Cross works in nonprofits as well, she was class of '95. So I think that, my family upbringing and combined with Holy Cross in terms of its ethos of men and women for others, I think really kind of pushed me into this career, which wasn't really a career back then. I don't know if you want me to keep going, but when I got back from the year of volunteer work and I came back to the East Coast, I didn't know what I wanted to do. I lived in Worcester, outside of Worcester. I thought I wanted to move to Boston where, because I was nearby that was a big city, or move to Washington DC where a lot of my roommates were and friends. But John Winter in the Career Center said, did you ever think about development? And I said, what's development? And we talked more about it, what that actually meant. And he connected me with a guy named Pat Cunningham, who I think is class of '85. And Pat Cunningham worked in New York City, and at the time he worked for the Archdiocese of New York. And the program there was that they were trying to help small Catholic parochial schools become sustainable. So small Catholic schools in New York City were always a big deal for helping teach kids and families who didn't have a lot of money, but get a good education. The outcomes were terrific. Typically, a lot of the kids went on to college. But the financial model was becoming challenging, because the religious communities who would tend to teach at those schools was diminishing. So they would have to hire lay teachers, you don't have to pay a Sister as much as you have to pay a layperson. So I think that caused like, oh my goodness, tuition is not covering the cost. And so they were trying to figure out a way could they raise money? Like private high schools, like St. John's in Shrewsbury or St. John's in Danvers, as BC High or Notre Dame Academy, they tend to raise money from their alums or parents. Pat Cunningham's job was to figure that out with some parochial schools in New York. There was a philanthropist who just passed away a couple of years ago, a guy named Richard Gilder, who was a Jewish, who founded a company Gilder, Gagnon, & Howe. Anyways, he believed in Catholic education and funded a lot of these schools. He believed in the outcomes and giving back in the community. And so he was essentially underwriting director and development positions. So the salary that a director of development would require. So there was an opportunity for me to work at a school called St. Columba Elementary School, which is on 25th between eighth and ninth without any experience at 23 years old. Siobhan: Is it still there? Sean: It is still there. But unfortunately, the school is closed and is now probably a private or a charter school. It Is the school... Had a couple famous alums, Whoopi Goldberg, graduated from... it's the school Whoopi Goldberg graduated from St. Columba, and as well as a singer from the sixties and seventies, Tony Orlando went to St. Colo. He's a guy who sang Tie A Yellow Ribbon and Knock Three Times. You ever hear those songs? No. Knock three times on the ceiling. Siobhan: Maybe. Sean: Yeah. I don't want to sing it. So what I had to do is work with the sisters and figure out a way to help raise money. And I learned a ton. It was fun. I started talking to some of the colleagues who were doing the similar work in the city, and we created a consortium of colleagues, I think we called it ourselves development, gosh, I forgot what we called it. Ourselves like Development Resources, Development Resource Group, I think DRG maybe. In any case, we would meet and just try to do some brainstorming and figure out how to solve problems. And we actually got some funding to actually help our little mini consortium. And I was there for about a year. It was fun. Siobhan: And then I know that you also did some foundation work, correct? Sean: Yeah. So after what? So I was doing that for a year, and then I had heard about this big company called CCS Fundraising and it's called... At the time it was called Community Counseling Service. And it's still around. It's a big, big fundraising company. And at the time, back when I was there, it's probably quadrupled since I was working there. Any case, we didn't have any money at St. Columba for professional development. So there was this big conference in New York called Fundraising Day in New York. And it is held every, it's the third Friday of June every year. So it's like a one day, it's one of the biggest fundraising conferences in New York. But to go to it, you know, it's like $600 or something like that. And we didn't have any money at St. Columba to do that. And so there was a scholarship opportunity. So if I wrote an essay to the committee that they would send scholarships out. So I wrote an essay to the committee and they underwrote my admission. So I was able to go to the event. And at the event I ran into an executive at CCS Fundraising and talked to him. He encouraged me to apply to CCS, which I did. And then I got a job with CCS Fundraising, which really did change my career for the good. And they sent me all around the world and helped train me in fundraising. And it was great. I was there for a long, long time. And that's where I did do some foundation work. So to continue on that, so when I got to CCS, I went to Yorkshire, England to do some work for the Diocese of Leeds and raise money there. So essentially CCS as a company that would get hired by nonprofits to actually help them raise money. Siobhan: Like a consultant. Sean: A hundred percent like a consultant. And it's weird because you'd be 24 years old or 25 years old and you're a consultant. And I remember a lot of my family friends is like, what do you know? You're just a kid. And there was a lot of truth in that, because I didn't know what I was doing. But the way the model worked at CCS was that they would train you, and there was actually different levels of consulting. And actually modern consulting firms like McKinsey have a similar model where you have the partners who are the thought leaders, and the business development people who actually find the clients. And they just need people to do the work. And those are the directors, the associate directors who essentially just took direction from the leadership. And in the case of going to the Diocese of Leeds, my charge was to work with parishes and coordinate, manage, design and execute what I would call mini-campaigns for each of those parishes. So I would go to the priest, I would orient the priest on the plan, we'd recruit a leadership team and go out and raise money. It was a very, very difficult assignment, but I learned a lot about resilience and persuasion and problem-solving and persistence and all that stuff, because it was a very intense five or six months. But it was fun. Get to live in Yorkshire in the middle of the winter when you're 24, 25 years old. That was great. Siobhan: I was going to say, that also just sounds really cool because you kind of get to dabble in so many different types of advancement. I know in development, I remember when I first learned about it, I was like, oh, that's like for schools. And I'm like, wait, no. There's fundraising for hospitals and political campaigns and nature organizations, which I want to get to eventually. Sean: And human rights organizations or arts and cultural groups. I think that that's a really good point, Siobhan, because where I got really lucky was that I, and it really serves me well right now at this stage in my career that I have a very diverse set of experiences and what we call multi-sector kind of experience. I'm not just a higher ed fundraiser, I've done every single type of nonprofit fundraising. And when you do that, you get to see where the commonalities are, and what the challenges are. Everything from a museum on Japanese sculptor named Isamu Noguchi, or to Cold Spring Harbor Laboratory in Long Island, with Dr. Watson, who just basically discovered DNA. So I've been very blessed with having been exposed, and working with very different kinds of organizations. And I know that at this point in my life, there's not a lot of people who have that kind of experience. And so that kind of becomes my professional marker, I guess. So the person who's done a lot of big complex organizations, but also a lot of small organizations too. Siobhan: So I have two questions on that. The first is, it's a soft question. In all of those different types of fundraising, which was your favorite, I guess what kind of fundraising was most enjoyable for you? Sean: I do the arts and cultural world because I find the board and the people to be very interesting and fun to work with. It is perhaps the hardest sector to work on because a lot of what we do is 400 billion is given away by people and corporations and foundations every year. And the top sector, it's religion, is probably the largest recipient of philanthropy, healthcare and education come in pretty close after that. So you're going to get a lot, it's not saying it's easier to raise money in higher ed, in healthcare, but in some ways it is because in healthcare it typically centers around solving a problem or the so-called grateful patient. "Dr X saved my life, I'm going to give him all my money or a lot of my money" and higher education is "professor Y saved my life and got me on the right path, so I'm going to give money there." Arts and cultural tends to be not necessarily the top priority people. It could be second or third or maybe sometimes fourth. And so it's harder sometimes, but I find it to be more interesting. And then in terms of my most enjoyable experience, probably when I worked in London again in 2000, when I got to do some work with the International Accounting Standards Board, which sounds very boring, but the job was very exciting because what the job was, was to raise money for an organization that was trying to harmonize accounting standards around the world. Siobhan: Oh, cool. Sean: I got to travel around Europe to actually interview executives on their willingness to support this cause, this kind of new plan. And it was just fun working on that kind of scale. One of the great things about this, that I've enjoyed about my career is that I have to learn about every kind of thing. I'm not an expert on accounting, but I have to be able to have a conversation about it. I'm not an expert on art museums, but I have to be able to at least have a conversation about it. And here at Audubon, I'm not an ornithologist, but I have to be able to talk about climate change and the importance of eelgrass in San Francisco Bay. Because what I'm doing is representing these organizations, and serving as the middle person between philanthropy and good causes. And that's on thing I think my profession's about. It's not about asking for money, in a weird way. It's really about creating an environment where you create opportunities for people who have money, who want to give away money, to do it in a way that they feel comfortable doing it. Siobhan: No, I feel the same way, especially in connecting with alums. It's not about asking them for money. It's about what did you love about Holy Cross and how can you support that again? Sean: Exactly. Siobhan: But you mentioned Audubon. And I just, so again, with advancement just being so vast, if I'm being honest, I didn't know that such an organization existed. When I saw that that's where you work, I was like, oh my God, of course that would exist. Sean: I'm going to have to do more work then, Siobhan to make sure you hear about this. Siobhan: But it makes sense. Birds are so important, and the environment is such, no pun intended, but a hot topic right now. But how did you, I guess, find that organization and what brought you there? Sean: Yeah. Siobhan: Is that one of your passions too? Is the environment something that strikes... Sean: It is, I think certainly climate change and birds over time. The truth is that they found me and reached out to me. And then, right now at this stage of my career, I think when I was a little younger... And I have some advice about careers too, but, and this is what I share with people, is that you really do want to go to a place where the people, you kind of vibe with the people that you're going to work with. I think mission is very important, but as you're building a career, it's very important to find people that believe in you, give you the resources to be successful in where you can learn. At Audubon, at this stage of my career, because I have a leadership role, I can control some of those things. I can control the type of culture I'm trying to create with my team, and which I think is very, very important for fundraisers. For fundraisers to stay, is actually understanding what makes motivates fundraisers and what motivates development. Because I think a lot of this is, there's some similar aspects I think to a really good fundraising personality. But Audubon, I think the reason why I'm here is because they wanted to grow. And one of the things I've learned about my career recently is that there's some people who are comfortable in a status quo environment. And then there's some people who just like to build things. And I'm certainly in the ladder, and part of this is because of my consulting background. I like to solve problems, and figure out a way to grow. I know that sounds like every organization wants to do that, but not necessarily. Because I think in order to do that, there has to be an alignment between the board and the leadership of the organization, and actually a really good case of why growth is needed. And then of course they need to invest. So you need to spend money to raise money. All those elements were in place when I was talking to Audubon about five and a half years ago with leadership. So if I see alignment between the Chair of the Board and the CEO, and if they kind of align with the Chief Development Officer or the person who's in charge of raising money, that's when really great things can happen. Because this is never, in my view, a money issue. There's plenty of money in this world right now. This is always a strategy problem. How are we getting the money? How are we telling our story? Do we have the mechanical pieces in place? Do we have the right people? Are they trained? Do we have the right leadership in place? Those are the things that staff ultimately control. And if they are in the right spot, and doing it the right way, the money should come. It's very difficult to get all that stuff figured out. And that's really, at the end of the day, that's what the work is. Is that I think good fundraisers have a vision for what the word will look like or feel like. At any given day, I know what kind of meeting I'm trying to design between a board member and my CEO, and I know what I want them to say and I know who I want in the room. So I'm always trying to get to that point. Not as easy as it sounds, because it just takes time to get all those things in place, and to make sure that the conversation's happening. And making sure you have answers to all the questions that funders want. So for instance, at Audubon we're... Bezos gives a wait a lot of money for climate, we spend a lot of time trying to figure out how to make that approach happen the right way. I don't want need to digress, but that's a lot of it how I think of it. Siobhan: No, and that's awesome. Actually, so I have a few questions that are going in different directions, so I'll see if I can loop them all together. So the first one is, I guess, what keeps you in this work? What drives your day? What kept your passion in the work that you're doing? Sean: Well, yeah, there were times, I remember in 2000, 2001 during the first dot com boom, I remember I would've been about 30 or so, there was a lot of people in my peer group trying to go to dotcom and early in internet stage companies. And I did talk to some people, this is after I got back from London. And I remember talking to some, what I would call philtech. Phil, P H I L technology, so philanthropy technology companies that were starting at that time and ultimately did not pursue them. And then on occasion, during the late two thousands or before the 2008 recession, could I parlay this experience into some kind of for-profit thing? I think ultimately, what kept me is, which is what you hear when you hear people give career advice when you're younger is, and I think there's a lot of truth to this, is if you actually like what you do and eventually you become good at it, then everything else takes care of itself. So I really do like what I'm doing, and I've become pretty good at it. And so then everything else takes care of itself. And being intentional about the different moves you make. And because designing a career is... I'm not saying it's a full-time job, but you cannot approach that casually. You have to be attainable about it. And what I mean by that is that whenever you go to an organization, and it doesn't really matter what sector we're talking about, but certainly in the fundraising sector, you want to understand not only how you're going to be successful there, but what will it lead to? What if you're successful at XYZ organization, will it give you an opportunity to grow within the organization or maybe even go to another organization, that type of thing. Depending on what you ultimately want to do. You don't have to become a Chief Development Officer. You can become the best frontline fundraiser in an area that you really, really love. And that's the great thing about this sector is that there's a lot of different diverse job functions. You have the development operations side, which is very much oriented towards tech people and people who are data-driven. The foundation relations kind of world, which really solid writers do well in that sector or that section of the work. And then frontline fundraisers are really usually a kind of sales salesperson orientation. Siobhan: I was going to say, as someone who is on the soliciting end of things, I feel like I'm a salesperson for Holy Cross, which I love because as someone, and you get this as someone who benefited from the product, it almost makes the job easy. But I was curious, so as someone, you weren't on both ends of the spectrum, so the soliciting side, which we've said isn't all about asking for money, but sometimes it comes down to, okay, here's my wallet. And then also the giving away of money. How would you, I guess, compare those roles? Because right now, as someone who's just starting out, I find the idea of grant giving and the other side of the work to be intriguing. Sean: It is intriguing. So my experience and foundations, I did some work with the MacArthur Foundation and the Gates Foundation, both those opportunities, I got to obviously work closely with them to understand more how they work. And over my career, I've got to work closely with some foundations. And over my career, I've probably felt the same thing that you're feeling, oh, it would be fun to get away money. But it's funny, they kind of have the same challenges in some ways because they... And I think that that actually helps you become a good fundraiser with foundations. To kind of boil this down, everyone has a job and everyone has to do things. So if you're a foundation officer, you have to do things, you have to give away money. And it is hard to give away money, because you're going to be evaluated on how the partnerships that you developed, did you squander the money or did you give the money away smartly? And if you gave the money away, did you do a good job following up in a and actually evaluating their efficacy? And that is hard. And there's a lot of pressure. And so if you orient yourself as a, now I'm going on the solicitor side, if you orient yourself to, I'm going to make this person's life easier, then you're talking to them like a person and you're creating a partnership. How can I help you with your job, or what you have to do? We're a good organization, we're going to communicate with you, we're going to spend your money the right way. Then it's a great thing. So you're not really asking them for money, you're really creating a partnership. And I think that that makes all the things in the world. But then if you think about designing strategies for a billionaire who wants to, some billionaire from Holy Cross calls you Siobhan and said, Siobhan, I want you to run a foundation for me and figure out... I want to give away money to human rights organizations and arts organizations in South America, and I'm going to give you a budget and you figure it out. So what would you do? You would probably start creating a network. You would go travel and see some, understand the issue. Go to South America, go visit museums, create a network of people, and then start to give away money. Yes, that would be fun. That would be really fun. But going to a big foundation and running a program, you do have to be a subject matter expert. Oftentimes, not all the time, because now there are a lot of foundations out there that I've been encountering that will hire a friend, someone they trust to actually help them with their foundation. I met this foundation recently where, all of a sudden they found themselves with a whole lot of money and they wanted to create this foundation because that's what the estate had directed them to do. And they're going to find the person that they trust. And so sometimes that person's not a subject matter expert, but they're a trusted advisor to the family. But if you're a subject matter expert in human rights, you're coming at it from a different direction. You're an academic that goes into a foundation. But I do think it's a growing, obviously a growing field as the wealth inequality continues to increase. I'll just give you a little tidbit on, this is one of my favorite facts. When I started in the business, mid-nineties, I would always go to the Hudson News in Grand Central and buy the Forbes 400, which would come out, I guess it would come on the fall. I'm trying to remember when it did. But I always loved that because I would go home on the train and just read it, and learn about the families who had wealth. And I quickly learned that not everybody, wealth and philanthropy are not the same thing. People with money and people who are philanthropic, there's like a Venn diagram in the middle. But to be the four hundredth, wealthiest person on that list, right back in the mid-nineties, the net worth was 400 million or something like that. It's a lot of money. What do you think it is today? Siobhan: It's more. Because I feel like... I was going to say, I feel like, because nowadays, and maybe it's because I work in fundraising, a million dollars doesn't seem like that much money anymore. Sean: Something like 1.7 billion. Siobhan: I was going to say at least a billion dollars. Sean: So why that's extraordinary. Not only how much it's gone up. Might be 1.4, but I know it's something like that. There's a whole lot of people below that. We don't even know who those people are. Siobhan: Wow. Sean: They're not necessarily publicly known. So the amount of people... It used to be rather, you used to be able to understand where the wealth was. And now I think you just don't, A very interesting world we live in now in terms of the relationship between wealth, philanthropy, and our business. There's a lot of new philanthropists coming on board that are coming out of the nowhere, partly because they're just not as well known. It's just more. There's more opportunity. That's why we're not really at a wealthy, it's not about money, it's about strategy. Siobhan: I was also going to say, I find... At least I can relate to least the capacity because sometimes, you use all the data that you have and you assume that someone has this profile, but you could either be over assuming, but then you could also be easily under assuming too. There are probably people that you don't think they would give maybe over a thousand dollars. But if you go about it, as you were saying, strategy, if you talk to them, if they're into music and you talk to them about the new performing arts center, you might inspire their generosity more than if you're talking to them about a new basketball court. Sean: I think that that's a hundred percent right. And I think, that's why I think it sounds a little old school. I think research can be a little overdone. I love research by the way. I think that my research team, they call me an, I'm an honorary researcher because on occasion, if I'm sitting in front of the TV or something like that, I'll go deep on some name and I just love finding these little nuggets of information. I'll send our director of prospect research these random emails. I said, look into this, look into that. Because at least at Audubon, I'm looking into people who care about climate, who care about birds, who care about... Siobhan: Again, that is so unique. Sean: Well, there's one, if you look on... Here's one of the cool things about birds besides the fact they're cool. If you go to... The Fish and Wildlife Service did a report on one of the most common outdoor activity, obviously gardening is actually probably the top. Birding is actually second or so. They estimate over 40 million people at one point in their life have gone out and watched birds, whether it's in their backyard or something like that. It's an awful lot of people. Siobhan: It is a lot of people. That's a fun fact. Sean: Yeah, it drives our work for sure. And we're doing this cool thing. This is kind of a little bit out of sequence, but we have this thing called Bird Song, which is this project we're doing. In fact, you can look on Spotify, and this has been in the New York Times. A music supervisor, a guy named Randall Poster who works with Wes Anderson and Martin Scorsese approached Audubon, and he got the bird bug over the pandemic because he was at home and listening to birds. He approached all of his musician friends, people like Jarvis Cocker and Yo-Yo Ma and Yoko Ono and Karen O and Beck to do songs inspired by Bird Song. And so he has 180 tracks. He's also asked his actor friends like Liam Neeson and Matthew McConaughey and Adrien Brody to read poems that are about birds, including a bird poem written by another Holy Cross alum, Billy Collins, who is a poet who wrote a poem about sandhill cranes in Nebraska. He has Conor Oberst from Bright Eyes reading that poem. Anyways, there's going to be a big album, a box set release, and all the money's going to go to Audubon. Siobhan: That's awesome. Sean: Birds are having a moment. Siobhan: Birds are having a moment. It's a bird's world and we're just living in it. Sean: It is. That's a good way of putting it, I'm going to borrow that. Siobhan: You can totally, as long as you give me copyright credit. Sean: I'll absolutely give you copyright, and all the royalties. Siobhan: Exactly. And I do want to just be cognizant of time, but as the podcast is about Holy Cross's mission and how it influenced your life, and I know you did talk about this a little bit at the beginning. I just wanted to hear more about how Holy Cross impacted your life and your work, and maybe Holy Cross' mission in addition to being men and women for others. Sean: I found a profession that I think in the beginning it might not have made sense, but I have to tell you now, at my age, there's a lot of people, a lot of friends who went to all lacrosse and other places are some ways jealous of this career because... So I have this ability to do well and do good. Use persuasion techniques or skills that could be implied to advertising or banking or some other sales job. But when I'm being reflective of the relationship between the effort and the work that I've applied my daily profession to the outcome, it completely aligns with my worldview of actually helping other people and helping organizations and helping the world, whether it's through art or healthcare or science or human rights or conservation. I feel pretty good about that. And I also feel very fortunate because I don't think I'd be in this profession if it wasn't for Holy Cross, partly because combined with how I was raised and also Holy Cross reinforcing some of those values and elevating them. And then, really the specific moment when Jonathan Winters actually said, hey, you should look into this job. And really made the connection between me as a recent alum and an opportunity with another Holy Cross person. So if Pat Cunningham's listening to this podcast, and I reach out to him once in a while, was a very influential person in terms of where I'm at right now, and I'm very grateful for that. So it's a fun profession. I encourage, I do a lot of connecting with other Holy Cross grads that have helped people. And there's a lot of Holy Cross people that I've met who are in this business, and you try to get together. Because I think there's a really interesting theme here in terms of what we do. And a lot of us are doing, in pretty good organizations, doing really, really good work. So celebrating that as a profession would be fun to do. I actually, Danita Wickwire, who is class of '94 joined my team recently. Which is incredible, because I told her, she reminds me a little bit of why I'm in this profession. Because if you go into this world of fundraising, it's hard to keep up with everything. But then, because she's here and because of our common history at Holy Cross, it's nice to have her because we were able to align around that a lot. And I think she participated in one of these podcasts as well. And she's a really, really influential and important leader in this space as well. Siobhan: Oh, that's awesome. She is an outstanding volunteer and name in our office. So our office is a big fan of Danita, she's great. Also, what I really like too that you said is, I don't know, I find that the job doesn't really feel like work and it's comforting to hear that doesn't change. Sean: It doesn't really. No, it doesn't change. I mean, listen, it's not saying it's easy all the time, but it's certainly fun. Siobhan: And then I guess you kind of touched upon this, but for someone starting out in this work, what is some advice you would give? And then I guess also, looking back on your journey that got you here, is there anything that you would've done differently? Sean: I don't think I have any regrets about choices I've made, also philosophically don't believe in that because I don't think it's helpful. But I think in terms of advice, I do think, and I know this sounds slightly cynical, so I soften this a little bit, but I really do feel it's important to go to a place where your boss and your colleagues believe and align with how you think about this work. I think often, sometimes I see folks make a mistake going to an organization for the mission only, and then what ends up happening sometimes, not all the time, is that the expectations aren't there. And then it can really be a hard place to be. One of the hardest things about this business is... It's a very optimistic, enthusiastic person, but I also know how hard this is and things can go wrong, and you might not have control over certain things. And so educating non-fundraisers, or orienting them about how this work actually unfolds happens with experience. So I'm able to do that with a little bit more ease than I did when I was younger. But be very intentional about your career. If you have a lot of the elements in place, that's great. If you're able to grow, that's great. Don't go for the money, so to speak, or for the mission, make sure everything else is in place. That's my advice. Siobhan: That's very deep. I think that's applicable to anything too. Sean: It is. But I remember, I give a lot of career advice and sometimes I see people, it looks really good, but you got to ask all the right questions, make sure you're asking the questions so you have it all figured out. Siobhan: Yeah. Then I guess, is there any type of organization that you haven't worked with yet that you'd want to? You said you've worked with most of them, but is there anything that maybe in your journey that you've seen... Sean: I was in Columbia last week, the country, because we do a lot of work hemispherically, so I was in Bogota and Cali. I really enjoy, where I think this is headed, and maybe it would be fun, is like this orientation about raising money in other parts of the world. I've done it before, I've done it in England, and it's different in every country and it's evolving and this cultural barriers of this and all that stuff. But I like the way the globalization in terms of how we're thinking about the NGO, bottom up. And also the importance of diversifying our space. Our profession has to be more intentional about how to do that and create space and opportunities for people of color and other backgrounds because there's a lot of history and reasons why it is what it is. And we have to continue to try to figure out ways to open up doors and opportunities that are just not going to happen naturally. You have to be forceful about that. So any place that is in that space. You know what, the weird thing about this space, and I talked to Ron Lawson about this, who's a Chief Operating Officer of a coalition, homeless coalition in New York. It's in a weird way, it's really hard to raise private philanthropy for some social justice issues like homelessness and hunger. Hunger, not as much as it used to be. But I'm always curious about why that is. And there are some organizations that kind of outperform. There's so much money that's given away and there's some sectors that are just not there yet. And that would be fun to understand more why that's happening and help with that too. Siobhan: Cool. I just wanted to see where you were headed next. Sean: I don't know. Siobhan: Nonprofit. Sean: Yeah, it's fun. I'm glad you're in this space and you should keep in touch, Siobhan, it'd be fun to see where your career's going to take you. Siobhan: I was going to say, I'll have you on speed dial. Sean: Good. Awesome. Siobhan: Awesome. And before I let you go, I just wanted to end on a fun little speed Holy Cross round. Sean: Sure. Siobhan: Very quick. Okay. What was your freshman dorm? Sean: Mulledy Siobhan: What was your hardest class? Sean: That economics class with Professor Chu. No, actually accounting class with Professor Chu. Yeah. Siobhan: Nice. Best professor you've ever had? Sean: Probably Professor Chu Siobhan: I see him sometimes, so I'll be sure to let him know. Sean: I think he just retired actually. I thought I just saw that he's retiring soon. Siobhan: He is, but he has his little research. Sean: Yeah, you can tell him that. Tell him, gave him a shout-out. I think I was, it might have been... That was his first year he got here, I think. Siobhan: Oh, that's so funny. Senior dorm? Sean: Carlin. Siobhan: Oh, nice. Sean: Yeah, Carlin Siobhan: Favorite spot on campus? Sean: I guess I liked the radio station. That was a great place to escape. Siobhan: Oh, cute. First meal you think of when you think of Kimball. Sean: Ah, that's good. Probably just like chicken fingers, I guess. They actually existed, I think that they did. Or that Turkey. There's like some kind of Turkey meal that was good there. Siobhan: Oh my goodness. The Thanksgiving Turkey dinner slaps. Best restaurant in Worcester. This is good because you're a local. Sean: Yeah, well the best restaurant right now that I was just like, wow, this is a pretty good restaurant. There's that sushi place on Park Avenue is really, really good actually. And then when I was there, I guess Arturo's was a great Italian place, but that's not, I think that's closed now. Best Breakfast place is probably Lou Roc's on West Boylston Street, which is a really, really good diner. Siobhan: Good to know. Everyone always talks about Miss Worcester's, I'll have to... Sean: Miss Worcester's is good, but Lou Roc's is a little further out, but it's excellent, excellent. Yeah. Siobhan: Oh, fabulous. All right. Your go-to study spot? Sean: The Library right side, as you're walking on the right side. Yeah, not the left side. Siobhan: Okay. And if you were going to campus right now, where are you going first? Sean: I am going to check out this new performing arts center which is the coolest looking building in Worcester, I think. Siobhan: Right? It kind of looks like an airport, but in a good way. Sean: It's a very cool, it's one of the coolest architecture buildings I've seen. And it's certainly one of the coolest things in Worcester. I think it's awesome. I want to go inside it. Siobhan: And then last question, your fondest Holy Cross memory. Sean: Fondest Holy Cross memory? Oh, I don't know. I really enjoy fall at Holy Cross. That's what I enjoyed the most. Yeah, and I like fall in Worcester. Yeah, for sure. Siobhan: That's a good answer. Sean: Yeah. Siobhan: Especially fall at Holy Cross is beautiful. Sean: Yeah, like a football game in the fall. That's probably it. Siobhan: Nice. Wow. Thank you so much for chatting with me. Sean: Thanks Siobhan. Siobhan: Taking the time out of your today. Sean: That was great, thanks. Thanks for the opportunity. Maura Sweeney: That's our show. I hope you enjoyed hearing about just one of the many ways that Holy Cross alumni have been inspired by the mission to be people for and with others. A special thanks to today's guests and everyone at Holy Cross who has contributed to making this podcast a reality. If you or someone would like to be featured on this podcast, then please send us an email at alumnicareers.holycross.edu. If you like what you hear, then please leave us a review. This podcast is brought to you by the Office of Alumni Relations at the College of the Holy Cross. You can subscribe for future episodes wherever you find your podcast. I'm your host, Maura Sweeney, and this is Mission-Driven. In the words of Saint Ignatius of Loyola, "Now go forth and set the world on fire." Theme music composed by Scott Holmes, courtesy of freemusicarchive.org.

People with Covid-19 often get sick because the body's inflammatory response to the virus overreacts. To tamp down that inflammation, researchers at the Feinstein Institutes for Medical Research and Cold Spring Harbor Laboratory, turned their sights toward famotidine, the active ingredient in a common over-the-counter heartburn medication with anti-inflammatory potential. On this bonus episode, we speak with the lead researcher of a unique clinical trial testing the safety and efficacy of famotidine for Covid. Tobias Janowitz, MD, PhD, AN Assistant Professor, Cold Spring Harbor Laboratory and adjunct professor at the Feinstein Institutes, shares the results of the study, as well as how the pandemic impacted their approach and led to an early success story for decentralized trials, repurposing medications and the importance of collaborating with other institutions. Chapters: 00:08 - Intro 01:39 - Safety, efficacy of famotidine for Covid 02:55 - What is famotidine? 04:45 - A fully remote trial 05:58 - Virtual trial strengths, weaknesses 07:00 - Famotidine dosage for heartburn, Covid treatment 08:12 - Studying famotidine for Covid 09:10 - Decentralized clinical trials 10:56 - New paradigms, new problems 12:02 - A national focus on decentralized trials 13:16 - Collaboration supports clinical excellence This bonus episode expands on Ep. 102 featuring Onisis Stefas, PharmD, executive director of VIVO Health. Listen to that episode, available in our feed, to learn about the Covid treatments available today. More from Northwell Health Watch episodes of 20-Minute Health Talk on YouTube. For information on our more than 100 medical specialties, visit Northwell.edu. And follow us on social media: Facebook – https://www.facebook.com/northwellhealth Twitter - https://www.twitter.com/northwellhealth Instagram - https://www.instagram.com/northwellhealth/  LinkedIn - https://www.linkedin/northwellhealth  

In this episode, we speak with Jason Williams, Assistant Director of Inclusion and Research Readiness at the DNA Learning Center at Cold Spring Harbor Laboratory. Jason is also lead for CyVerse Education, Outreach, and Training – the U.S. National Cyberinfrastructure for Life Science. Jason received his B.S. in Biology from SUNY Stonybrook in 2004, then worked as a technician in several labs at Cold Spring Harbor, and then transitioned to multiple roles in the DNA Learning Center In 2009. We discuss an article Jason and colleagues recently published in Science, entitled “Achieving STEM diversity: Fix the classrooms. Outdated teaching methods amount to discrimination”. We also talk about the nuance and complexities around improving diversity, equity and inclusion in STEM education, in planning conferences, and in running scientific societies. Have a listen! Show Notes: Paper: J. Handelsman, S. Elgin, M. Estrada, S. Hays, T. Johnson, S. Miller, V. Mingo, C. Schaffer, and J. Williams. (2022). Science 376:1057-1059. https://pubmed.ncbi.nlm.nih.gov/35653460/ Twitter Handles Liz Haswell Twitter @ehaswell Ivan Baxter Twitter @baxtertwi Jason Williams Twitter @JasonWilliamsNY

As 2022 comes to a close, we look back on five exciting medical advances coming from clinical researchers at Northwell Health and the health system's Feinstein Institutes for Medical Research. In the last year alone, investigators published more than 2,500 papers in peer-reviewed journals. In this episode, we spotlight studies that made strides against endometriosis, diabetes, lupus, pancreatic cancer and (yes) Covid-19.  Chapters:   02:05 – Treating pancreatic cancer in a petri dish | Matthew Weiss, MD  05:51 – A powerful lupus treatment in the pipeline | Richard Furie, MD 10:25 – Famotidine for Covid | Tobias Janowitz, MD 14:45 – A noninvasive test for endometriosis | Christine Metz, MD  19:12 – Treating diabetes with ultrasound | Sangeeta Chavan, MD Meet our guests:  Matthew Weiss, MD, professor in the Institute of Cancer Research at the Feinstein Institutes and the deputy physician-in-chief and surgical director in the Cancer Institute at Northwell Health Richard Furie, MD, chief of the Division of Rheumatology at Northwell and global principal investigator on the LILAC (Part A) clinical trial Tobias Janowitz, MD, PhD, assistant professor, Cold Spring Harbor Laboratory; adjunct professor at the Feinstein Institutes; and principal investigator of the trial studying famotidine for Covid Christine Metz, PhD, professor in the Institute of Molecular Medicine at the Feinstein Institutes and co-director of Research OutSmarts Endometriosis (ROSE) study Sangeeta Chavan, PhD, professor at the Feinstein Institutes for Medical Research

Neste episódio do Podcast CRUZAMENTO, André Correia e Daniel Guedelha conversam com Jorge Santos da Silva, Fundador e CEO da MoonLake Immunotherapeutics sobre biotech, investimentos e inovação e, sobre como Portugal é visto por alguém com uma grande experiência internacional. Jorge Santos da Silva, is a co-Founder of MoonLake and has served as the Chief Executive Officer of MoonLake since July 2021, being also a Director of the Board. Prior to MoonLake, he was at McKinsey & Company, Inc. from September 2007 to June 2021, where he was a Senior Partner and led the Pharmaceutical & Medical Products Practice, the Biotech group and the Biosimilars group and advised international biopharmaceutical and biotechnology companies on corporate and business-unit strategy, commercial operating models, R&D, organizational design, M&A and joint ventures. Dr. Santos da Silva was a Postdoctoral Fellow at Cold Spring Harbor Laboratory, NY (USA) and holds a Ph.D. in Neuronal Cell Biology from the University of Turin (Italy) and a MSc in Molecular Biology from the University of Glasgow — Institute of Biological and Life Sciences (United Kingdom) and the European Molecular Biology Laboratory, Heidelberg (Germany). He is also a professor and Board Advisor at the School of Medicine at the Minho University in Portugal. Outras referências feitas no episódio: MoonLake Immunotherapeutics (website) Contactos: CruzamentoPodcast.com cruzamentopodcast@gmail.com LinkedIN: Cruzamento Twitter: @cruzamentofm Facebook: @podcastcruzamento YouTube: Podcast Cruzamento

  Vidcast:  https://youtu.be/BM9C_nTcJR0   Cystic Fibrosis is due to a genetic mutation that leads to insufficient moisture in body secretions and thickened respiratory mucus.  Geneticists at New York's Stony Brook University and the Cold Spring Harbor Laboratory have now demonstrated the possibility of using gene therapy with so-called antisense oligonucleotides to create better functioning versions  of the cell water-controlling protein CFTR, short for cystic fibrosis transmembrane conductance regulator.  This will someday result in a set of more normally-functioning lungs, pancreas, liver, gastrointestinal tract, and reproductive organs for those with cystic fibrosis.   https://www.nature.com/articles/s41467-022-30668-y   #cysticfibrosis #cf #genetherapy #cftr #aso #antisenseoligotides  

Vincent travels to Cold Spring Harbor Laboratory to speak with David Baltimore, John Coffin, and Harold Various about the discovery in 1970 of retroviral reverse transcriptase and its impact on life sciences research. Hosts: Vincent Racaniello Guests: David Baltimore, John Coffin, and Harold Varmus Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Fifty Years of Reverse Transcriptase (Cold Spring Harbor Laboratory) 50th Anniversary of RT discovery (Mol Biol Cell) RT in virions of Rous sarcoma virus – Temin (Nature) RNA-dependent DNA polymerase in tumor virus particles – Baltimore (Nature) Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv

Rather than focusing on traditional technology transfer metrics, RK Narayanan and his team at Cold Spring Harbor Laboratory measure their success in terms of their ability to create value in the long term.  In today's episode, RK, who is the Senior Director of Business Development and Technology Transfer at Cold Spring Harbor Laboratory, explains their approach to long term value creation, which is built on a foundation of sustainable relationships. RK also shares the life-changing technology that his team were involved in taking to market, the people who make up his ‘lean machine' team, and some of the key industry partnerships that they have cultivated. RK's career began on the research side of things, but exploring alternative opportunities led him to the world of technology transfer, and his excitement about this field is contagious!    In This Episode: [00:52] Introducing RK Narayanan, today's guest.   [01:58] RK shares what his journey in the US has consisted of, since he moved here from India to pursue his PhD.  [06:03] What RK's Business Development (and Technology Transfer) team at Cold Spring Harbor Laboratory focuses their efforts on.  [06:53] Cold Spring Harbor Laboratory's research budget, and where their funding comes from.  [08:22] People who make up RK's team.  [09:57] Why RK and his team don't focus too heavily on metrics, and what they use as measures of success instead. [11:16] How Cold Spring Harbor Laboratory supports start-ups that come out of the laboratory. [12:24] RK explains what the concept of value creation means to him and his team. [14:50] Partnerships which RK and his team have been cultivating over the past few years.  [16:36] RK shares one of his office's biggest success stories. [18:21] The biggest challenges that RK and his team are facing at the moment. [19:27] Examples of Cold Spring Harbor Laboratory's efforts to enhance diversity, equity, and inclusion.   [22:11] RK's thoughts on the 2022 AUTM Annual Meeting, and the value that he sees in being a part of the organization. [23:59] Three wishes that RK has for the future of technology transfer at Cold Spring Harbor Laboratory.   Find RK: Email LinkedIn  

Matt Ridley's books have sold over a million copies, been translated into 31 languages and won several awards. His books include The Red Queen, The Origins of Virtue, Genome, Nature via Nurture, Francis Crick, The Rational Optimist, The Evolution of Everything, and How Innovation Works. His TED talk "When Ideas Have Sex" has been viewed more than two million times. He writes a weekly column in The Times (London) and writes regularly for the Wall Street Journal. As Viscount Ridley, he was elected to the House of Lords in February 2013. He served on the science and technology select committee 2014-2017. With BA and DPhil degrees from Oxford University, Matt Ridley worked for the Economist for nine years as science editor, Washington correspondent and American editor, before becoming a self-employed writer and businessman. He was founding chairman of the International Centre for Life in Newcastle. He was non-executive chairman of Northern Rock plc and Northern 2 VCT plc. He also commissioned the Northumberlandia landform sculpture and country park. He founded the Mind and Matter column in the Wall Street Journal in 2010. He won the Hayek Prize in 2011, the Julian Simon award in 2012 and the Free Enterprise Award from the Institute of Economic Affairs in 2014. He is a fellow of the Royal Society of Literature and of the Academy of Medical Sciences, and a foreign honorary member of the American Academy of Arts and Sciences. He is honorary president of the International Centre for Life in Newcastle. He has honorary doctorates from Buckingham University, Cold Spring Harbor Laboratory and University Francisco Marroquin, Guatemala. He is married to the neuroscientist Professor Anya Hurlbert. They have two children and live in Northumberland in the north of England.

Maria Luisa Pineda is the Co-founder and CEO of Envisagenics, which was founded in 2014 as a spinout of Cold Spring Harbor Laboratory. Given that there are over 30 million people in the United States who suffer from genetic diseases or cancer, which could be caused by mutations affecting RNA splicing, Envisagenics aims to accelerate the development of innovative therapeutic solutions for RNA splicing variants with the help of its AI platform. Dr. Pineda has over a decade of experience as a biologist. She was awarded an endowment of $2 million dollars from the Goizueta Foundation and an NIH fellowship with the Minority Access to Research Careers program during her undergraduate training. She then went on to obtain her Ph.D. from the Watson School of Biological Sciences at Cold Spring Harbor Laboratory as an Arnold and Mabel Beckman graduate student and a William Randolph Hearst foundation scholar. On this episode, we discuss her experience in navigating the science startup world. --- Support this podcast: https://anchor.fm/theia-hc/support

Ingenuism -- We believe that the basic source of innovation is human ingenuity—the process of using creative thinking to solve productive challenges. But to benefit from ingenuity, we need to understand the conditions that allow it to function, generate new ideas, and solve challenging problems. Today's episode we discuss the origins of the Covid-19 virus. What are the implications of the Lab Leak Theory? What is the probability the virus came directly from Nature? What are the implications for progress, human well being? Does Gain Of Function make sense?Yaron discusses this and much more with Matt Ridley, co-author with Alina Chan of Viral: The Search For the Origins of Covid-19. Matt is an award winning science writer. His books have been shortlisted for six literary awards, including the Los Angeles Times Book Prize (for Genome: The Autobiography of a Species in 23 Chapters). He has been a scientist, a journalist, and a national newspaper columnist, and is the chairman of the International Centre for Life, in Newcastle, England. Matt Ridley is also a visiting professor at Cold Spring Harbor Laboratory in New York.Buy the book on Amazon at: https://www.amazon.com/Viral-Search-C...#OriginOfCovid #MattRidley #AlinaChan #Ingenuism #LabLeakTheory #GainOfFunctionResearch #Viral #Covid-19

This week, we're getting into the Halloween spirit, taking a look at all things spooky. First, we'll learn about the history of the holiday and how candy became so integral. Then we'll learn about haunted inns, and why Frankenfoods aren't really that scary. We'll also explore Día De Los Muertos and some foods associated with the holiday. Further Reading:On the history of halloween: Go here for a more in-depth look at the history of Halloween, and here for a closer look at how candy corn came to be.To learn about the Ear Inn, check out their website. If you want even more New York City history, read this NYTimes article about Early Manhattan and the Ear Inn's origins.For information about Miguel's bakery, visit their website. Check out this article in the NYT to learn more about how they make pan de muerto, or watch this video to see how they make another popular item, conchas. To Learn more about CRISPR technology and other innovations in gene editing, click here. Go here to learn more about Dr. Lippman's work with the Cold Spring Harbor Laboratory. Keep Meat and Three on the air: become an HRN Member today! Go to heritageradionetwork.org/donate. Meat and Three is powered by Simplecast.

ブランドのカリスマ性とタトゥー/PCに貼るステッカー、大学の校章デザイン、スポーツチームのロゴデザイン、企業ロゴのデザイン、ポッドキャストのアートワークデザインについて話しました。Show notes Researchat.fm ep100 … researchat.fmの読み方について議論した回 Researchat.fm ep84 … 格ゲー回 ポッドキャストのアートワーク … researchat.fmなら灰色の風呂場のタイルにresearchatと書いているアレです。 Researchat.fmのTwitter タコスとタトゥー 坂井直樹 企業のカリスマ性とタトゥー コカコーラの刺青 … “コカ・コーラ大好き青年だった彼は、 背中にコカ・コーラの入れ墨を彫りたいと考える。それだけれは終わらなかった。彼は入れ墨をした背中を広告媒体にしようと電通にプレゼンテーションする。媒体料は１億円。突拍子もない企画だったが、電通の窓口は真剣に検討しようとしたという。しかし、入れ墨は牛の焼き印（ブランディング）にイメージ が重なるなど、まだアメリカ社会でもタブー視されていた。結局、広告には向かないと没になる。” アイスマンとタトゥー … “エッツィの凍りついたミイラには、銅器時代の入れ墨が良好な状態で残っている。合計50片を超える入れ墨が頭から足先まで全身を覆いつくすように刻まれている。これらは針を使って彫られたのではなく、皮膚に細かな傷をつけ、そこに炭を擦り込むことで描かれたものだ” るろうに剣心 ドカベン … 傑作。土佐丸高校の犬丸じゃなくて、犬神です。大変もうしわけございませんでした。 井岡タトゥー問題 村上隆 … 現代芸術家 DOB君 村上隆全集 … DOB君の由来についてはここに書いてます！ Thorlab … 自作顕微鏡用のメーカー Thorlab Tシャツ … 冷静になってみなおすと… 学会のTシャツ … 国際学会にいくと謎のリュックと共にもらえることがある。 NAIST … 奈良先端科学技術大学院大学 NAISTのTシャツ … JAISTしかなかったのでJAISTを貼っておきます。 スウェットパンツ … 私が言いたかったのはスウェットパンツ ハーバードの校章 鋼の錬金術師 dessan Harvard's motto … VERITASの解説記事 神学部 … Divinity School TAS … “TASとは、TVゲーム等においてエミュレータの機能を用いたタイムアタックを行う事、およびその競技名。” Ivy league … “Brown University, Columbia University, Cornell University, Dartmouth College, Harvard University, the University of Pennsylvania, Princeton University, Yale University” Ivy Leagueの校章 Oxford大学の校章 Cambridge大学の校章 パリ大学の校章 ボローニャ大学の校章 MITの校章 ミシガン大学の校章 スタンフォード大学の校章 東京大学の校章 京都大学の校章 東京工業大学の校章 一橋大学の校章 筑波大学の校章 慶應義塾大学のペン 開成のペン 早稲田大学の校章 同志社の校章 立教学院の校章 青山学院の校章 新島襄 Phillips Academy … 新島襄さんの出身エリート校 Phillips Exeter Academy … ザッカーバーグや望月新一先生が出身の学校は姉妹校のこちらです。 University of Massachusetts Amherst … UMASのアマースト校 北京大学 Researchat.fm ep7 … シドニーブレナー回 シーサー … “名前は「獅子（しし）」（元はサンスクリット語のライオン、シンハー）を沖縄語で発音したものである。八重山方言ではシィーシィー、シーシ－という。スフィンクスや中国の石獅、日本本土の狛犬などと同じく、源流は古代オリエントのライオンと伝えられている。犬という説もあるが、沖縄に関連の深かった中国や南方からの影響を考えてやはり獅子であろうという意見や、またその音からも獅子と断言される事がある。中国南部や台湾には風獅爺、風獅と呼ばれる石造の獅子を風除けの守りとして設置する風習があり、これらがシーサーと訳されることがある。” OIST　… 沖縄の雄。沖縄科学技術大学院大学 UC … The university of California UC Berkeley レッドソックスのロゴ Researchat.fm ep23 … 大谷回 レッドソックスのダメなユニフォーム レッドソックスの靴下マスコット 大阪近鉄バッファローズ 鍛治舍巧監督 … 名将 岐阜県立岐阜商業高校 Golden State Warriors Cold Spring Harbor Laboratory Johnson and Johnson moderna … すばらしい会社 而今 IPA … India pale ale キャノン … Kwanonかっこいい！！！ octocat NASURA … NAISTのキャラ。思っているよりかっこよかった。 “物性犬、地球犬、情報犬、びけん以外の研究所犬キャラ情報をお待ちしております” by okaさん　 ドロイド君 ダンボ君 dockerのクジラ SNK NEOGEO FF6 スターオーシャン 鳥山明先生 三越のライオン ハンガリーの鎖橋 金剛組 虎屋 Researchat.fm ep5 … 羊羹の回 levi's 笑い男 りさちゃん、ちゃっとくん、CasXくん 深津さんの東京オリンピック記事 Researchat.fm ep111 … 鏡像異性体ポリメラーゼの話 Researchatの”シン”アートワーク … これだ！！！！ Editorial notes ポッドキャストのアートワークをしっかり考えないとね。多方面に先に謝罪しておきます。(tadasu) TBD (coela)

Adam Siepel, Professor of quantitative biology at Cold Spring Harbor Laboratory, discusses the applications of evolutionary genomics in anthropology, infectious disease, and cancer.  The Bioinformatics CRO is a fully distributed contract research company that serves the computational biology needs of biotechnology companies, with a focus on genomics. https://www.bioinformaticscro.com/

In this bonus episode of Ocean Matters, producer Izzie Clarke explores the very first theories of how islands are formed from Charles Darwin and his time on HMS Beagle. Joining her is Alistair Sponsel, Historian of the Life Sciences at Cold Spring Harbor Laboratory and Senior Research Fellow in Science, Technology & Society at Harvard University, who explained where the crew's research began and how this has shaped our understanding of remote islands. If you want to find out more about Darwin, Alistair has written a book on his life called “Darwin's Evolving Identity: Adventure, Ambition, and the Sin of Speculation” Ocean Matters is a Fresh Air production for the Bertarelli Foundation.       See omnystudio.com/listener for privacy information.

Matt Ridleyis the author of books that have sold well over a million copies in 32 languages. He has been a scientist, a journalist, and a national newspaper columnist, and is the chairman of the International Centre for Life, in Newcastle, England. Matt Ridley is a member of the House of Lords in the UK and also a visiting professor at Cold Spring Harbor Laboratory in New York. In conversation with Nick Weinberg, Director of Content @ Company Ventures.

Dr. Dennis Carroll has a doctorate in biomedical research with a special focus in tropical infectious diseases from the University of Massachusetts at Amherst. He was a Research Scientist at Cold Spring Harbor Laboratory where he studied the molecular mechanics of viral infection. He has over 30 years of leadership experience in global health and development. He served as the Director of the U.S. Agency for International Development’s Emerging Threats Division. Dr. Carroll was responsible for providing strategic and operational leadership for the Agency's programs addressing new and emerging disease threats. He currently heads the Global Virome Project, an international partnership to build the systems and capacities to detect and characterize future viral threats.For Your Listening Pleasure for these Lockdown / Stay-At-Home COVID and Variants Times - For all the radio shows available on The 'X' Zone Broadcast Network visit - https://www.spreaker.com/user/xzoneradiotv.Our radio shows archives and programming include: A Different Perspective with Kevin Randle; Alien Cosmic Expo Lecture Series; Alien Worlds Radio Show; America's Soul Doctor with Ken Unger; Back in Control Radio Show with Dr. David Hanscom, MD; Connecting with Coincidence with Dr. Bernard Beitman, MD; Dick Tracy; Dimension X; Exploring Tomorrow Radio Show; Flash Gordon; Imagine More Success Radio Show with Syndee Hendricks and Thomas Hydes; Jet Jungle Radio Show; Journey Into Space; Know the Name with Sharon Lynn Wyeth; Lux Radio Theatre - Classic Old Time Radio; Mission Evolution with Gwilda Wiyaka; Paranormal StakeOut with Larry Lawson; Ray Bradbury - Tales Of The Bizarre; Sci Fi Radio Show; Seek Reality with Roberta Grimes; Space Patrol; Stairway to Heaven with Gwilda Wiyaka; The 'X' Zone Radio Show with Rob McConnell; Two Good To Be True with Justina Marsh and Peter Marsh; and many other!That’s The ‘X’ Zone Broadcast Network Shows and Archives - https://www.spreaker.com/user/xzoneradiotv

#19 — Prepare for some serious houseplant envy in this episode of The Microscopists, as we talk to the multi-talented Jennifer Waters (@JenCWaters), Director of the Nikon Imaging Center at Harvard Medical School. As well as directing the core facility and creating the successful Microcourses YouTube channel, Jennifer runs the Quantitative Imaging course at Cold Spring Harbor Laboratory. She also received a Chan Zuckerberg Initiative Imaging Scientist award in 2019. And she still finds time to water her 100 plus houseplants!We'll discuss Jennifer's favorite microscope, her career highlights – and challenges, and why she needs four different sewing machines.Join us for this insightful and inspiring chat as we learn more about Jennifer's passion for plants, painting, and pepperoni pizza.Watch or Listen to all episodes of The Microscopists here: https://themicroscopists.bitesizebio.com/

#19 Prepare for some serious houseplant envy in this episode of The Microscopists, as we talk to the multi-talented Jennifer Waters (@JenCWaters), Director of the Nikon Imaging Center at Harvard Medical School. As well as directing the core facility and creating the successful Microcourses YouTube channel, Jennifer runs the Quantitative Imaging course at Cold Spring Harbor Laboratory. She also received a Chan Zuckerberg Initiative Imaging Scientist award in 2019. And she still finds time to water her 100 plus houseplants! We’ll discuss Jennifer’s favorite microscope, her career highlights – and challenges, and why she needs four different sewing machines. Join us for this insightful and inspiring chat as we learn more about Jennifer’s passion for plants, painting, and pepperoni pizza. Watch or Listen to all episodes of The Microscopists here: http://bit.ly/the-microscopists-pds

Dr. Hayes interviews Dr. Norton.   TRANSCRIPT SPEAKER 1: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   [MUSIC PLAYING]   DANIEL F. HAYES: Welcome to JCO's Cancer Stories, the Art of Oncology, brought to you by the ASCO Podcast Network, a collection of nine programs covering a range of educational and scientific content, and offering enriching insights into the world of cancer care. You can find all of the shows, including this one, at podcast.asco.org.   [MUSIC PLAYING]   Dr. Norton has stock and other ownership interest in Samus Therapeutics, Codagenix Inc, Martell Diagnostic, and Medaptive Health Inc. He's received honoraria from Context Therapeutics, Prime Oncology, the Sarah Lawrence Lecture, Context Advisory Board, Oncology Pioneer Science Lecture Series, Sermonix Pharmaceuticals, the Cold Spring Harbor advisory board, Codagenix, Agenus, and the Cold Spring Harbor external advisory board.   He has served as a consultant or provided advice to Context Therapeutics, Prime Oncology, the Context Advisory Board, Oncology Pioneer Science Lecture, Martell Diagnostic, Sermonix, Codagenix, Agenus, Medaptive Health, and the Cold Springs Harbor Laboratories. He has received expense reimbursement for travel and accommodations from the Oncology Pioneer Science Lecture Series, the BCRP Programmatic Review Meeting, the Breast Cancer Research Foundation, the American Association of Cancer Research, and Cold Spring Harbor Laboratory.   [MUSIC PLAYING]   Today my guest on the podcast is Dr. Larry Norton. Dr. Norton has been instrumental in so many facets of oncology it's hard to go through, but particularly, in breast cancer, and especially related to applying mathematical models of cancer kinetics that he developed with Richard Simon at the National Cancer Institute, and applying them really, to dose density strategies for chemotherapy and breast cancer, which we'll discuss. Dr. Norton was raised in suburban New York.   He received his undergraduate degree at Rochester University, his medical degree at the Columbia University College of Physicians and Scientists. And then he did his residency at Einstein Associated Hospitals in the Bronx. He then went on to complete a medical oncology fellowship at the National Cancer Institute from 1974 to 1976 and stayed there an extra year. And then he returned to New York and joined the faculty at Mount Sinai in 1977, where he stayed for about a decade.   He then moved to Memorial Sloan Kettering, where I think most of us think he was born and raised and lived his whole life. He's held many positions there. And particularly, he was responsible for really building the breast medical oncology service and starting the Evelyn Lauder Breast Center. He now sits in the Norman S Seraphim-- did I pronounce that correctly, Dr. Norton?   LARRY NORTON: Yes, you did.   DANIEL F. HAYES: Chair in Clinical Oncology, he's authored over 450 peer reviewed papers. He's won too many awards for me to list, as have most of my guests on this program. But in particular, he's won the triple crown, in my opinion. And that's the Karnofsky, the McGuire, and the Bonnadonna awards.   At least those of us in breast cancer would strive to win all three of those. And importantly to this series, he served as president of ASCO from 2001 to 2002, has served many roles at ASCO and has had a major footprint in where ASCO is today. Dr. Norton, welcome to our program.   LARRY NORTON: Great pleasure to be here. Thank you, Dan.   DANIEL F. HAYES: So we'll start with some of the origin stories. I know you weren't bit by a radioactive spider and got spidey powers. But I've known you for a long time.   And I know, really, your first love was music and that you started out to be a professional musician. Can you give us some background? What were your instruments? I know you went to Rochester specifically to be in music. And feel more than free to do some name dropping, because I think some of the people in music are people we'd all recognize.   LARRY NORTON: Well, I don't know whether that would be totally right. I've known a lot of people in music. My first love was music.   I grew up in Long Island, was able to commute in with one bus and one subway to Greenwich Village in the '60s, which was, really, the hotbed of much of what was going on in music to this day. I didn't even realize it was a golden age. I remember all the giants, Bob Dylan, when he was a very young kid in town, in small coffee houses.   But it was also in close proximity where a lot of the jazz scene was happening, and just to take the A Train would be very easy to get up into Harlem, where there's a lot of jazz things going on. Like a lot of kids growing up on Long Island, I had some musical education. I started off with the clarinet, went quickly into saxophone in terms of music. But I played a whole variety of instruments.   Like everybody else, I play guitar. I played percussion. I played bongos behind beat poets and was very excited to be really part of that scene.   I think one of the major turning points for me, actually, was the Vietnam War. Because like a lot of people of my generation, it did not seem to be reasonable war. And even McNamara wrote a book later saying, yep, sorry, it was a mistake. We were looking for things that could interest us and also help us serve our country in ways other than sacrificing our lives in Vietnam.   That's how medicine got into my life. It seemed to be the right compromise. Fortunately, starting off in Rochester which had the Eastman School of Music, which was a great influence on me, and a fantastic school, and has evolved continuously to be an even better school now.   It has a very active jazz program now, which didn't exist at that time. We had to do jazz on the sly, which was very easy to do, because there are a lot of jazz clubs in Rochester at that time. And it was really very easy to play jazz all night and then to play classical music all day. And that was totally, totally a great experience.   We were young. We didn't have to sleep at all. But I hankered to get back into New York. When the opportunity arose to go to medical school, I was fortunately chosen to go to Columbia, where I actually was able to play music and at the same time go to the medical school. But after a while, as all of us in medicine know, it becomes all consuming.   And so the medicine part of it just slipped. When it came to a lot of my friends from the old days up until the present day, very little performing, I've done a couple of benefits. I'll do the one namedrop with Elton John, because he's been so terrific at raising money for breast cancer research through the Breast Cancer Research Foundation. I had the great honor of being able to play with him twice--   DANIEL F. HAYES: How did you meet Elton John? I mean, it's not like you walk down the street and say, oh, hi, I'm Dan Hayes.   LARRY NORTON: Mutual friends, mutual friends in the arts, basically, one of our closest friends, close friend of his, close friend of mine, someone named Ingrid Sischy was a fantastic writer and editor, very involved with Andy Warhol in the beginning, and then continued a career in art criticism and art writing. And she was a friend of everybody and a close friend of Elton's and a close friend of mine. And so I think she made the original introduction. And he's really been terrific.   But the music is put aside, although I do play every day. I still keep that as a very important part of my zen escape from other stresses of life. Although, music itself has its own stresses.   The good thing about jazz is improvisation. So it's an immediate feeling, no such thing as a wrong note. You hit a wrong note, and you play around it. And it becomes a right note. And so music is still a very important part of my life.   DANIEL F. HAYES: That's terrific. Actually, I interviewed Hyman Muss a few weeks ago. And he and some others have introduced me to tying flies for fly fishing.   And it's sort of the same thing. I can take 15 minutes and tie a fly. I'm not sure it looks like anything official-like. But it's not medicine for a while, and that's good.   LARRY NORTON: Yeah, but medicine--   DANIEL F. HAYES: The other thing--   LARRY NORTON: I want to get back to this for a second, because I mean,   DANIEL F. HAYES: Yeah.   LARRY NORTON: It's not a separate thing. I mean, music and-- especially my early music education just taught me a lot that's really helped me in my career in medicine. I think it's very important for people to know. The talent for music is a talent to practice.   Essentially, anybody who can speak can-- has enough control of tones that they can actually do something with music. I'm not sure how much is really inborn ability. I'm not sure there is such a thing as a talent in that regard. But some people can practice for long hours successfully. And some people can't.   And I think that that's something that may be inborn. I don't know. I'll leave that to the developmental psychologists. But that is a very important trait, obviously, in medicine.   You have to spend a long time studying. You have to learn a lot. You have to concentrate a lot. You have to be able to concentrate on individual patients, when you're taking care of them. And that's been very important, but it's also empathy.   Music teaches you to feel what other people are feeling. You're not going to be a good musician unless you know how you're affecting your audience in a profound way. And you can sense when you're losing your audience, and you can change the direction you're going in. And when you hit something right, you can play it.   And that ability to feel what other people are feeling, I think, is really essential to be a good clinician. And music teaches you that. I think arts in general teach you that.   DANIEL F. HAYES: Actually, I hadn't thought about it. Do you think that your music and your mathematic leanings are tied together too?   LARRY NORTON: There is a tendency for mathematicians to be musicians, not true quite vice versa. Although they are-- good musicians really are mathematicians. But they don't know it.   A lot of people think math is the written equation, and it's not. It's a certain approach toward nature. Thinking in spatial ways, for me, thinking of shapes, and the way shapes form, the way shapes move over time and space, then you learn the tools for being able to write it down which is the actual mathematical notation.   DANIEL F. HAYES: Yeah.   LARRY NORTON: And the same thing with music, I mean, music isn't the notes on the page. I mean, that's a very poor reflection of what sounds you're making. It's the sounds. It's the sounds, and they go up and then down. That's spatial, and they go forward in time.   And so they're temporal, and they have meaning. It's not just random sounds. They have meaning. They connect to each other, and they tell a story, as we say in the jazz world. And the notes are a poor reflection of that.   Some of the best musicians I know can't read music. And as a matter of fact, it used to be said that if you want to be good jazz musician, you shouldn't learn to read. Because if you learn to read, you'll cheat. And you should be able to play by ear. And that's what's going to make you a better musician.   So I think math and music are very closely aligned. You have a problem to solve, when you think about it, and in novel ways that are not verbal. And the non-verbal way of thinking in music and in math are very similar, I think.   DANIEL F. HAYES: So let me segue onto how you changed paths. I know that it was-- I've heard you talk about it was a discussion with Dr. Ron Bloom, who I think has remained a good friend of yours, and then in association with Dr. Regelson at Roswell Park. Can you tell us about that?   LARRY NORTON: Well, Ron got me-- I mean, Ron, great, great oncologist, retired now, and his wife Diane also very, very important in the cancer world through her leadership of organizations. They both went to University of Rochester same time I did. I was actually perplexed at the end of one semester.   So both Ron and Diane were at the University of Rochester, the same I was. And I was perplexed at the end of one semester, because I had several opportunities to do things in the summer coming forward. One of which was very music oriented, and it was a very exciting possibility. But I was at that time considering a change in direction very strongly.   Math was one of the things that was drawing me. The question, should I become a professional statistician? That was the course that was turning me on mostly at that time. I thought physics was an incredible art form and was intrigued to that.   But I also had music that was drawing me. And also the question, of what could keep me helping people, and helping my nation, and keep me from necessarily bearing arms in Vietnam was a big concern. And I met Ron on the stairs of the Rush Rhees Library at the University of Rochester, a famous library, that by the way, has a famous ghost associated with it. That's a whole different story.   He said that he had this unbelievably wonderful experience the previous summer by working at Roswell Park Memorial Institute in Buffalo, New York State Cancer Research Institute, particularly under a guy named William Regelson who was just totally inspirational to him. And that was one of his major motivations to spend his career in cancer medicine, which I didn't even know it. I had another connection to Bill Regelson is that my father and his father actually knew each other. Because they were in businesses that touched.   His father ran a Catskills resort. And my father was a professional writer and travel editor at The New York Post. And so that there was that connection. So that when I relayed the story to my parents, they said, oh, we know Regelson.   So well, one thing led to another. And on a cold and rainy night, I took a bus into Buffalo, New York. And I met Bill Regelson in the laboratory at Roswell Park Memorial Institute.   It was late at night, and it was freezing rain, kind of miserable night. And he asked me a lot of very tough questions and was not very pleasant toward me. But the end of the interview, he says, I like the way you think. And I'd like to offer you an opportunity to work with me this summer.   And I jumped at that opportunity. And it was really, truly the turning point in my life in many ways. Because I, eventually, many years later ended up marrying Bill Regelson's daughter. My current wife--   DANIEL F. HAYES: I was not aware of that.   LARRY NORTON: Yeah. Rachel, the love of my life, it was an extraordinary experience, because I got very close to family. And she was in New York at Columbia, at Barnard, the same time that I was in medical school. And so that's how it all came about.   But anyway, Bill was really an inspirational character for many people of my generation who were in contact with him. Because he was just filled with enthusiasm, and energy, and optimism. You remember, the early days of oncology were very special. And by the way, if you want to catch a glimpse of that, it tends to be this book, The Death of Cancer. I'm giving it a big plug, fantastic book that captures the whole history of his life and cancer.   But the early days is very important for people to recognize what it was like in those early days. It was just an enormous challenge just to get people to pay attention. The possibility that drugs could actually be useful in the treatment of cancer, and it was often ridiculed. I can tell you a little story later about my early experiences when I came to New York in that regard.   DANIEL F. HAYES: So did you know you were going to be an oncologist when you went to med school? Or did that--   LARRY NORTON: I'll tell you two of the turning points in that regard that I think are particularly interesting. One is, at the very beginning of that summer, Bill Regelson brought me-- in those days, the labs were right next to the clinic, the inpatient service. And he brought me right from the lab a few steps in to see a patient who was admitted to the hospital with a pelvic tumor.   I don't know what type, didn't register in my mind at that time, but a pelvic tumor that had grown very large. And it actually had eroded out into the skin and was large, and infected, and bleeding, and just awful. And the patient was in terrible pain.   And he said, we're going to treat this patient with a new drug that I think is going to help her. And it's called methotrexate. And he treated with methotrexate, and I saw the I saw the medicine go into her arms.   And over the next few weeks, during that summer, I saw this tumor shrink down. I saw the skin heal over. I saw the pain go away. And it was, I'm seeing this monster eating this woman from the inside out. And I'm seeing just this yellow chemical going in there, and the monster being defeated.   It was like magic. It was something just beyond conception that, actually, you could take something that awful and that terrible, and actually give it medicine, and actually make it go away. And I said, this is a world I can't turn my back on. This is a world I have to be in.   This is just a magical, wonderful world, where you can actually heal things that couldn't be healed by other ways, I mean, totally beyond surgery, totally beyond radiation. And here's medicine going in. So that hooked me.   But at the very end of the summer, and toward the very end of my time there, another thing happened which would be a good segue. But also very important is the real person running medicine A at Roswell Park at that time was this person named Jim Holland. And Jim Holland was not there all summer, because he was riding a horse. And he had his daughter, one of his daughters on the horse.   And the horse was acting very, very jittery. And he was a little afraid of what the horse would do. So he went close to a fence, where he could actually unload the daughter, so she can grab on to the fence. And the horse didn't bolt and crushed his hip against the fence.   And so he was out with a fractured hip or pelvis the entire summer. But he was well enough toward the end of the summer to come in and speak to the summer students. And he came in, and he sat in a chair in the middle of the room. And all the summer students who gathered around him-- if I thought Bill Regelson had energy, to see this tornado of a personality in the room, with his loud booming voice and his probing questions, his clear intelligence and enthusiasm for his field and dedication to it was just inspirational.   And so it was a crescendo of a summer for me. And that was it. The experience of Bill Regelson, the experience of Jim Holland, I knew that I was stuck. And even though other things were attracting my attention, nothing was going to capture my life as much as the medical oncology.   DANIEL F. HAYES: You went on then to work with him for 10 years at Mount Sinai.   LARRY NORTON: Right.   DANIEL F. HAYES: In addition to what you've said, his obnoxious ties also always stood out for the rest of us. But those 10 years must have been unbelievable. Because the guy never quit thinking, at least in my experience with him.   LARRY NORTON: I mean, there's so much to say about Jim Holland. I had the honor to speak his funeral, the sadness to speak at his funeral, but it was the honor to speak at his funeral related some of the stories. But there's so much to talk about him that it's actually worth a whole book, even an opera, with the bigger than life personality he was.   But he captured something that I think was very important. And some of the early pioneers that we were talking about before really captured which is, I mean, these were real pioneers. I'll just give you a little side story. I mean, I came into grand rounds once, when I was working with him late, as I usually am to pretty much everything.   But nevertheless, I came in a few minutes late, and everybody was gathered around. And I remember it was a thoracic specialist, a pulmonologist, who was actually conducting grand rounds. And as I walked in the door, he says, how come you're late, Larry? Were you out there saving lives?   And everybody roared into uproarious laughter. Because medical oncology was the last step before the cemetery. Hopeless situations would all come to us. And then we'd give them drugs and not help people whatsoever.   And of course, I felt this deep humiliation. I was a young doctor at the time, and all these great, senior people, great luminaries were arrayed around. But that was the attitude of a lot of people in medicine at that time is that hopeless situations, send it to them, they'll take care of it. They'll hold hands, whatever.   And to see where we are today, and how many cases we cured, and how many patients we've cured, and how well we managed things, certainly, we don't cure enough. And you and I and our whole community is working hard on that. But we do cure a whole lot of people, and we do help their lives.   And we do keep them functioning for a longer period of time with the medicines. So the people that went into the field at that time and actually established the field of oncology, medical oncology, at that time were really had to have a real pioneering spirit. And so Tom Frei obviously pops to mind in that regard, and many others. I could give a long list--   DANIEL F. HAYES: Well, I should say, I had the great privilege of training with Tom Frei and the pleasure of interviewing Dr. Freireich who, sadly, passed away a few weeks ago. I did not get to interview Dr. Holland. But because of his friendship with Dr. Frei, Dr. Holland adopted me as well, even though I was never working with him directly.   And the three of those guys, I think our listeners need to understand, they were really cowboys. And they did things that we would now just, I think, repel, just have you can't do that sort of thing. But they did it, because they had to. As you said, there was nothing else to do. It took a special personality.   LARRY NORTON: Totally-- I mean, everything you're saying is-- I agree with. But also, that's why we are where we are today is because they took chances, because they had a vision, and they attacked that vision very, very aggressively. And I'll do one more namedrop in music that is one of my and still friend is Quincy Jones.   And Quincy Jones had this wonderful phrase in terms of jazz improvisation that was really very important to me. Sometimes, Larry, you have to jump without a parachute. And how do you get into an improvisation? You just start.   And then it has a life of its own. And the better you get, the more experience you get, the better you start it, and the better you're going to develop it. But you just got to start. Hit the first note, doesn't matter what it is.   And that kind of spirit of jumping in into it was really, very important. And I think that's something I really miss from modern oncology. If we're going to talk about where we are now compared to where we are then, a lot of things have changed that are very positive.   Obviously, the amount of science that we have to draw from now is just astronomically greater than what we had in the early days, when we're talking about very primitive things. The whole Norton-Simon thing was all about attacking cell division, the best way of attacking cell division. We're so far beyond that in so many ways. That's one of the bigger changes.   Our access to information, I mean, I had a question. I have to go to the library and got to cart catalogs, and pull books off the shelf, and open them up, and spend hours and spend days finding out one piece of information that now I can find out in about 15 seconds, if my fingers are slow on the keyboard, 15 seconds. And so that's it.   But one of the major things is that it was all about concepts then. It was all about principles. The principle that antimitotics could actually make tumors shrink and could be beneficial. That's a principle.   Combination chemotherapy is a principle. Dose dense sequential therapy, if you take it into further development of my area as a principle. And the overarching concepts on patient centrality of it also is that the early clinical trials were very small trials. Because each and every patient was a valuable piece of information.   They were almost collections of anecdotes. And obviously, we've evolved way past that in very positive ways. But what you learned from the individual patient was extremely important to that generation of pioneers rather than large numbers. And I think we moved away from that.   DANIEL F. HAYES: Actually, I'm going to interrupt you, because I think almost everybody I've interviewed has stories like you started out with. I saw a patient who I couldn't believe responded to X or Y. And I have the same stories.   And I'm hoping our young folks still believe that's as important as filling out the meaningful use things on their documentation. I told my own son, I want him to be a doctor and not a documenter. You need to document, but you need to be a doctor. Can I segue into--   LARRY NORTON: We ought to spend the whole podcast on that topic someday.   DANIEL F. HAYES: No, yeah, let's do that.   LARRY NORTON: Because the thing is-- well, because I think that the thing is, when you're taking care of a patient, and you're thinking, obviously, we're always thinking what's best for the patient, all of us. But you're also thinking of gathering information in a verbal way about the patient. So you can talk about that patient to your colleagues, or write it as case reports, a series of case reports is a different mindset than when you're thinking about how am I going to fill out my electronic health record?   And I think the mindset differences, and I frequently say to the younger people that I teach or that I'm in contact with, that they grew up in a digital world. And I grew up in an analog world. And the way you think in an analog world is very different than the way you think in a digital world. Maybe it's for the better. I mean, only history will tell, but I just miss that kind of analog thinking. Much of what we have today is because of it.   DANIEL F. HAYES: Let me take you into your role in modeling and especially with the so-called Norton-Simon hypothesis. How did you hook up with Richard Simon? And what did he teach you? Because I find him to be a fascinating person.   LARRY NORTON: Oh, a fascinating person, and obviously, one of the really important people in my professional career. The math was in there. Because along with, I mean, I studied math. I had studied math in college, and I was--   DANIEL F. HAYES: I should-- describe it. Just for a minute, describe what it is for our listeners.   LARRY NORTON: Oh, the Norton-Simon hypothesis and the--   DANIEL F. HAYES: Yes.   LARRY NORTON: All right. Oh, yeah, well--   DANIEL F. HAYES: Briefly, briefly.   LARRY NORTON: It's very simple is that way before my time, Skipper Schabel and colleagues at Southern Research Institute had described the way experimental tumors in their laboratory grew which was exponential. And they made the observation called the Log Kill hypothesis, which is the Log Kill rule which is a given dose of given drug kills a percentage of the cells that are present rather than an absolute number of cells, which is actually counterintuitive. It shouldn't be that way if you think about it in terms of biochemistry, but it is that way.   And we were all taught the Skipper Schabel model and Log Kill hypothesis. We were all taught that. And I was in the clinic taking care of a patient with Hodgkin's disease, nodular sclerosis Hodgkin's disease. And this patient had [INAUDIBLE] involvement with Hodgkin's disease.   Remember, I was working with Vincent Davita, a great influence on my life, Bruce Chabner, Bob Young, many people who-- George Canellos, who you know very well, great luminaries doing lymphoma therapy as a clinical associate at the National Cancer Institute. Hampton's patient is they had to Hodgkin's disease, got MOPP chemotherapy, roared into complete remission. Basically, two cycles of MOPP, was in complete remission. I've been involved in oncology since the early days of MOPP to show you how long I've been involved in oncology.   And I got four more cycles, because we give six cycles no matter what. We're two cycles beyond complete remission in that setting. And it was about a year. And the patient came back with mediastinal lymphadenopathy. The biopsy showed that was exactly the same lymphoma. Put him back on MOPP chemotherapy, and he responded again and went back into remission.   I don't recall whether it was complete remission or partial remission. And I said, this is really fascinating, because the math was already in my head at the time. Because I thought I want to graph it out and show how well it fit the Log Kill hypothesis. And it didn't fit at all.   I mean, it just didn't make any kind of sense. From a mathematical point of view, you couldn't make the equations fit. And about that same time, I became aware that others were describing that tumors were not really growing exponentially-- solid tumors were not growing exponentially as Skipper had shown in his laboratory models, a certain leukemia named leukemia 01210.   But rather, by a very strange curve called a Gompertz curve, which was developed in 1825 by Benjamin Gompertz to fit actuarial data, actually, not anything in terms of biology. And that's an S shaped curve. So it looks exponential at the beginning. And then it bends over and eventually seems to try to reach a plateau size.   And so I went back, and I applied the Skipper Schabel model mathematically to the Gompertz curve. And I realized that, for this individual patient, it would make a whole lot of sense if the tumor, when it was growing quickly, regressed more than when it was growing slowly at a very large size. In other words that the hypothesis is that the rate at which it would shrink is proportional to its rate of growth.   And since, in a Gompertz curve, the rate of growth is always changing, the rate of shrinkage changes as a function of time as a tumor shrinking down. And that was of germ the idea. And then the question is how to test it.   Under contract Arthur Bogden in Massachusetts did some animal modeling for us. And we published my first paper actually that showed tumors were growing in a Gompertzian fashion. And in fact, a subsequent paper showed that they regressed also in the Gompertzian fashion which is what the Norman-Simon hypothesis is.   Almost immediately thereafter, a couple of implications, in terms of cancer therapeutics, and I want to get back to that. Remind me to get back to that later on. Because this is around 1977 or so that all this was really becoming clear.   So it was actually one patient that made me think of it. I mean, frankly, it was one patient's experience that made me think of it. And that's what you were saying before, Dan, is the importance of learning from each individual patient.   DANIEL F. HAYES: And actually, it's gone on to be tested in many, many trials. But probably the most definitive was run by Marc Citron and CLGB under your guidance. And I just want to say a few words, because Marc passed away just a few weeks ago. He was really instrumental in ASCO and very, very generous to the foundation. We'll miss him greatly. But that trial of 97--   LARRY NORTON: 41.   DANIEL F. HAYES: 9741, demonstrated that dose density was superior to giving things in big doses for longer periods of time. Let me ask you about--   LARRY NORTON: I just want to second there what you're saying about Marc. I mean, just an incredible human being, an incredible person, incredible clinical scientist, and he was actually the first community clinician to chair a major national trial from a co-operative group which was just an intentional decision. I believe, you were involved in that decision, actually, Dan, Hyman Muss, certainly.   DANIEL F. HAYES: Marc and I started in a group at the same time. And we grew very close. I miss him. Let me ask you to look into your crystal ball for a minute and that is with precision medicine and targeted therapy. Does the Norton-Simon hypothesis still apply to that? Do you think chemotherapy still--   LARRY NORTON: Oh, yes. Oh, yeah, yeah. Well, first of all, I mean, I'm not-- now we're getting into sophisticated science topics here. But the thing is that I'm not, to this day, I'm not sure I have chemotherapy works.   I don't think that all of chemotherapy effect is just killing dividing cells. First of all, it's mathematically impossible. Does chemotherapy, does cytotoxic therapy affect the relation cell to its microenvironment? Does it affect its relationship to the immune system? These are all things that are under active investigation and active study at the present time.   There's more to what we do every day in terms of giving chemotherapy than just killing dividing cells. Chemotherapy can be very precise. I mean, methotrexate and dihydrofolate reductase, we talked about it before. It's very, very precise therapy, hormone therapy, tamoxifen and the estrogen receptor.   So we've been talking about precision medicine for a long time. It's just that our level of sophistication in terms of likely targets has changed. But still, it works. It's a law that fast things, things that grow faster regress more quickly than things growing more slowly how you return them. And I think that there are important lessons there that we still have to learn about cancer biology.   And that got me into some very exciting areas with [INAUDIBLE] and colleagues and to cell seeding theory with cancer, for example. And that story is evolving. And more data is becoming available there and much more sophisticated mathematics that will apply to those days that I hope I will have time to work on in the next few years to be able to actually establish those principles.   But I still think that we're doing something wrong if you're talking about a crystal ball which is that-- and it relates to what I just said before. We're so self-hypnotized into thinking that cancer is a disease of cell division. The vast bulk of our targeted therapeutics are oriented toward molecules that are related to mitosis.   You hear talk, that'll be a very specific talk about molecular pathways starting with genomics and [INAUDIBLE] signaling. At the end of the slide, it says, invasion, metastasis, and growth. It's a nice little package. And that's the answer. Well, I mean, that's a big cloudy area.   I mean, those are different things. Those are separate things. Those all have their separate biology. But they're all related. It is totally true.   And how are they related? And why are they related is one of the very important topics that we have to wrestle with, because that's what we really have to perturb. And I think that the, again, crystal ball guessing, or at least where I'm putting my energies now is we have all these incredible tools for developing medicinals that can attack molecules.   Are we attacking the right molecules by focusing in cell division? Should we be looking more toward perturbing tumor microenvironment relationships? Should we look at more sophisticated ways of using the immune system as one element in the tumor microenvironment, one of many in the tumor microenvironment, to accomplish the goals that we have to accomplish?   And are we actually looking at the right things in terms of molecular analysis in cancer by looking at pathways that are concerned with cell division primarily and secondarily with other things? Or should we be looking at molecular networks and molecular pathways in a more sophisticated fashion? Just like the early days of oncology, we have to be willing to take intellectual chances. And that's something I'm seeing much less of now than I did if you go back half a century.   DANIEL F. HAYES: We can go on with this one for a long time too. And we probably will the next time we get to sit and have a drink together when the pandemic goes away. I think it relates to dormancy. And I don't think we understand dormancy or how it is broken and how to treat it.   I have two things, and we're running out of time. One of those is you probably, in my opinion, have been the king of understanding the importance of philanthropy in our field, especially in relationship to what I see directly, which was your relationship with Evelyn Lauder and her husband, Leonard, of course, in the Breast Cancer Research Foundation. But I'd just like you to emphasize to the folks coming in the field how important that philanthropy is.   I think some of them believe it's dirty to get involved with that and ask people to give money. And you and other people I think have taught a lot of us that these folks want to help us. And it's important to address that in a dignified way.   LARRY NORTON: We're all in this together. I mean, I think that's the important thing to recognize as a physician or as a scientist. I said in a paper once that just as all of us are either actual or potential healers, all of us are actual or potential patients.   Cancer is a very important problem that needs to be solved. And people have to solve in every way they can, with our intellectual ability, our hard work in the clinic, our hard work in the laboratory. And people who are working hard in other fields who accumulate some element of wealth, or even people that just in normal life contribute small amounts, a lot of people doing small amounts adds up to a lot of money also. I mean, they're all part of the same process.   I mean, the importance of philanthropy is that-- and it goes back to what Evelyn said which I quote all the time. She was very instrumental in the building of our first breast center at Memorial Sloan Kettering and then our second breast center, which is freestanding building at Memorial Sloan Kettering. She and Leonard involved in every way and not just in terms of philanthropy, but actually thinking through the problems and helping solve them and design in every way.   When we built the first building that we had, we actually raised a little bit more money than we needed for the actual physical structure. So the question is, what to do with it? And obviously, a research fund at Memorial was established.   But then in terms of where else to go with it, she invited me over to her place in New York overlooking Central Park. And we sat in the kitchen, and we drank tea. And I said, what I perceive, and with my colleagues, I'm not the only one, obviously, who's perceiving this, is an explosion of science, basic science in understanding cancer, and an incredible collection of clinical investigators that can do clinical trials, and do large clinical trials as well as pilot clinical trials in our institutions. But I didn't see the connections being very tight. Because we were in different worlds, speaking somewhat different languages.   And we had to tighten those connections somehow and do something translating scientific advances in the laboratory into clinical benefit. It also allowed the scientists to understand what the clinical problems were and how to have the approach, and how we're going to do this. And she said, I've worked around creative people all my life in my professional life. And I know, you've got to identify the right people first of all.   So that's a little bit of a talent. But that the main thing is that when you identify them, you've got to give them freedom to use their imagination and the security to know that if they do something good and it doesn't work out, that they're not going to lose their job. Freedom and security is the secret of making progress in the field.   And I said, that's what we need. We need a foundation that can give the right people the freedom to use their imagination and the security to know that as long as they do good work, they're not going to lose their funding in a more traditional grant mechanism. And that's really where it started. So the whole thing is all based on that, is to get the right people and to give them freedom and security. And another part of it I just want to mention is networking to give people--   DANIEL F. HAYES: So let me focus this.   LARRY NORTON: OK.   DANIEL F. HAYES: Breast Cancer Research Foundation, how many people are you supporting? And how much money did you give this year? Just to give--   LARRY NORTON: Oh, about, oh, I mean, it's about 200 or so or more than that. Investigators, it's international at the present time. This year has been a tough year, and the next few years probably, because of COVID, because of the pandemic.   It's been a tough year. But in general, we've probably given away about a billion dollars. But it's not given away. It's actually an investment, investment in the future.   DANIEL F. HAYES: Yes. I agree.   LARRY NORTON: And it's all about bringing people together. New investigators come in, and they're used to gladiatorial combat when it comes to grant acquisition is that they have to fight against the people to beat them out. And what we reward is people working together and sharing ideas. And phenomenal things have occurred in that direction, phenomenal, huge programs in metastasis and molecular biology, Translational Breast Cancer Research Consortium which has been a fantastic thing that we've helped support. So it's really been a joy.   DANIEL F. HAYES: It's been great. Final 1 minute, the other thing you've done as well or better than most is mentoring. And I personally want to thank you for helping me in my career.   But probably, your greatest success is mentoring Cliff Hudis who's now the CEO of ASCO and is responsible for ASCO continuing to be probably the world's greatest oncology professional society. Actually not probably, in my opinion, for sure. So for that, I thank you.   We've run out of time, unfortunately. I think you and I could go on for another hour or so with this stuff which is what's fun about my getting to do this. But I want to thank you for all you've done for the field, for all you've done for so many of us in the field, and most importantly, for the patients who have benefited from what you've done.   It's pretty remarkable. This has been so much fun for me to get to interview so many of the pioneers. But you certainly rank up there at the top. So thank you very much for your time and look forward to talking to you later.   LARRY NORTON: Thank you so much for the kind words and for inviting me to do this with you, Dan. Thank you.   [MUSIC PLAYING]   DANIEL F. HAYES: Until next time, thank you for listening to this JCO's Cancer Stories, the Art of Oncology podcast. If you enjoyed what you heard today, don't forget to give us a rating or review on Apple Podcasts or wherever you listen. While you're there, be sure to subscribe so you never miss an episode. JCO's Cancer Stories, the Art of Oncology podcast is just one of ASCO's many podcasts. You can find all the shows at podcast.asco.org.   [MUSIC PLAYING]

Podcast Producer Meagan Cantwell talks with Pamela Soltis, a professor and curator with the Florida Museum of Natural History at the University of Florida and the director of the University of Florida Biodiversity Institute, about how natural collections at museums can be a valuable resource for understanding future disease outbreaks. Read the National Academies of Sciences, Engineering, and Medicine report Biological Collections: Ensuring Critical Research and Education for the 21st Century. This segment is part of our coverage of the 2021 AAAS Annual Meeting. Also on this week's show, Katharina Schmack, a research associate at Cold Spring Harbor Laboratory, joins producer Joel Goldberg to talk about giving mice a quiz that makes them hallucinate. Observing the mice in this state helps researchers make connections between dopamine, hallucinations, and mental illness. This week's episode was produced with help from Podigy. Listen to previous podcasts. About the Science Podcast Download a transcript (PDF). [Image: christopherhu/Flickr; Music: Jeffrey Cook] Authors: Joel Goldberg; Meagan Cantwell See omnystudio.com/listener for privacy information.

Podcast Producer Meagan Cantwell talks with Pamela Soltis, a professor and curator with the Florida Museum of Natural History at the University of Florida and the director of the University of Florida Biodiversity Institute, about how natural collections at museums can be a valuable resource for understanding future disease outbreaks. Read the National Academies of Sciences, Engineering, and Medicine report Biological Collections: Ensuring Critical Research and Education for the 21st Century. This segment is part of our coverage of the 2021 AAAS Annual Meeting. Also on this week's show, Katharina Schmack, a research associate at Cold Spring Harbor Laboratory, joins producer Joel Goldberg to talk about giving mice a quiz that makes them hallucinate. Observing the mice in this state helps researchers make connections between dopamine, hallucinations, and mental illness. This week's episode was produced with help from Podigy. Listen to previous podcasts. About the Science Podcast Download a transcript (PDF). [Image: christopherhu/Flickr; Music: Jeffrey Cook] Authors: Joel Goldberg; Meagan Cantwell See omnystudio.com/listener for privacy information.

Podcast Producer Meagan Cantwell talks with Pamela Soltis, a professor and curator with the Florida Museum of Natural History at the University of Florida and the director of the University of Florida Biodiversity Institute, about how natural collections at museums can be a valuable resource for understanding future disease outbreaks. Read the National Academies of Sciences, Engineering, and Medicine report Biological Collections: Ensuring Critical Research and Education for the 21st Century. This segment is part of our coverage of the 2021 AAAS Annual Meeting. Also on this week’s show, Katharina Schmack, a research associate at Cold Spring Harbor Laboratory, joins producer Joel Goldberg to talk about giving mice a quiz that makes them hallucinate. Observing the mice in this state helps researchers make connections between dopamine, hallucinations, and mental illness. This week’s episode was produced with help from Podigy. Listen to previous podcasts. About the Science Podcast Download a transcript (PDF).

In 1993 three giants in the field of neural research got together to discuss their work and how it related to learning and memory. Dr. Timothy Tully, former Senior Staff Investigator at the Cold Spring Harbor Laboratory, Dr. Eric Kandel, 2000 Nobel Prize winner in Physiology/Medicine, and the late Dr. Patricia Goldman-Rakic, Professor of Neuroscience at the Yale University School of Medicine, spent time discussing their different research approaches and what they were discovering about how human beings learn, acquire new information, and hold on to it. From Pavlov to genetics, these scientists were opening new doors to understanding how …

Deep Thoughts: Science and Social Justice is an interview podcast where we take a deep dive into the struggles, triumphs and personal stories of minorities in the sciences, arts and public service. The goal of these interviews is to have candid, first person conversations about the role of race, gender, and socioeconomic status in politics, the sciences and beyond.This episode features Dr. Prem Premsrirut, CEO of Mirimus- a biotech company in Brooklyn, NY. Dr. Premsrirut was an MD/PhD Medical Scientist fellow at the SUNY Stony Brook School of Medicine and Cold Spring Harbor Laboratory, where she focused on determining the role of tumor suppressor genes in tumor maintenance of lung adenocarcinoma. There she pioneered a novel approach for the speedy generation of cancer mouse models. Her research laid the groundwork for Mirimus which she founded and is currently CEO.We will discuss how we worked together to open an emergency COVID-19 testing facility in Brooklyn, NY in less than six weeks during the height of the pandemic. The challenges and setbacks associated with this and how other labs can model this approach across the world. Learn more about Mirimus at mirimus.com and read about the labs efforts here (https://www.idtdna.com/pages/community/blog/post/confronting-the-pandemic)Follow Deep_Thoughts_Podcast on instagram for all updates and share this podcast with your friends!

BUSINESS ACCELERATOR - Starting soon: https://londonreal.tv/biz/ 2021 SUMMIT TICKETS NEW MASTERCLASS EACH WEEK: http://londonreal.tv/masterclass-yt LATEST EPISODE: https://londonreal.link/latest DENNIS CARROLL serves as the Chair of the Global Virome Project Leadership Board. Dennis previously served as the Director of the U.S. Agency for International Development’s (USAID’s) Pandemic Influenza and other Emerging Threats Unit. In this position, he led USAID’s Emerging Pandemic Threats program – a global effort to combat new disease threats before they can become significant threats to human health. Dennis was responsible for providing strategic and operational leadership for the agency’s programs addressing new and emerging disease threats, which included leading the agency’s response to the H5N1 avian influenza and H1N1 pandemic viral threats. Dennis was initially detailed to USAID from the U.S. Centers for Disease Control and Prevention as a senior public health advisor in 1991. In 1995 he was named the agency’s Senior Infectious Diseases advisor, responsible for overseeing the agency’s programs in malaria, tuberculosis, antimicrobial resistance, disease surveillance, as well as neglected and emerging infectious diseases. In this capacity Dennis was directly involved in the development and introduction of a range of new technologies for disease prevention and control, including community-based delivery of treatment of onchocerciasis, rapid diagnostics for malaria, new treatment therapies for drug-resistant malaria, intermittent therapy for pregnant women and “long-lasting” insecticide-treated bed nets for prevention of malaria. He was responsible for the initial design and development of the President’s Malaria Initiative. Dennis officially left the CDC and joined USAID in 2005 when he assumed responsibility for leading the USAID response to the spread of avian influenza. Dennis has a doctorate in biomedical research with a special focus in tropical infectious diseases from the University of Massachusetts Amherst. He was a Research Scientist at Cold Spring Harbor Laboratory where he studied the molecular mechanics of viral infection. Dennis has received awards from both the CDC and USAID, including the 2006 USAID Science and Technology Award for his work on malaria and avian influenza, and the 2008 Administrator’s Management Innovation Award for his management of the Agency’s Avian and Pandemic Influenza program.

Dr. Dennis Carroll has a doctorate in biomedical research with a special focus in tropical infectious diseases from the University of Massachusetts at Amherst. He was a Research Scientist at Cold Spring Harbor Laboratory where he studied the molecular mechanics of viral infection. He has over 30 years of leadership experience in global health and development. He served as the Director of the U.S. Agency for International Development’s Emerging Threats Division. Dr. Carroll was responsible for providing strategic and operational leadership for the Agency's programs addressing new and emerging disease threats. He currently heads the Global Virome Project, an international partnership to build the systems and capacities to detect and characterize future viral threats.

Dr. Dennis Carroll has a doctorate in biomedical research with a special focus in tropical infectious diseases from the University of Massachusetts at Amherst. He was a Research Scientist at Cold Spring Harbor Laboratory where he studied the molecular mechanics of viral infection. He has over 30 years of leadership experience in global health and development. He served as the Director of the U.S. Agency for International Development’s Emerging Threats Division. Dr. Carroll was responsible for providing strategic and operational leadership for the Agency's programs addressing new and emerging disease threats. He currently heads the Global Virome Project, an international partnership to build the systems and capacities to detect and characterize future viral threats.

Dr. Dennis Carroll has a doctorate in biomedical research with a special focus in tropical infectious diseases from the University of Massachusetts at Amherst. He was a Research Scientist at Cold Spring Harbor Laboratory where he studied the molecular mechanics of viral infection. He has over 30 years of leadership experience in global health and development. He served as the Director of the U.S. Agency for International Development’s Emerging Threats Division. Dr. Carroll was responsible for providing strategic and operational leadership for the Agency's programs addressing new and emerging disease threats. He currently heads the Global Virome Project, an international partnership to build the systems and capacities to detect and characterize future viral threats.

Dr. Dennis Carroll has a doctorate in biomedical research with a special focus in tropical infectious diseases from the University of Massachusetts at Amherst. He was a Research Scientist at Cold Spring Harbor Laboratory where he studied the molecular mechanics of viral infection. He has over 30 years of leadership experience in global health and development. He served as the Director of the U.S. Agency for International Development’s Emerging Threats Division. Dr. Carroll was responsible for providing strategic and operational leadership for the Agency's programs addressing new and emerging disease threats. He currently heads the Global Virome Project, an international partnership to build the systems and capacities to detect and characterize future viral threats.

Scientists and policy makers have a couple of things in common: they dedicate themselves to a cause larger than themselves. Getting results that positively impacts other people or a certain issue is what drives these special people to overcome every rejection and test failures that they come across with. Policy-making isn’t the easiest field to enter into but for Mike Stebbins, PhD, it’s an incredibly challenging yet very fulfilling thing to be a part of. Mike Stebbins is the President of Science Advisors, a science and health consulting firm that he founded in 2018 to provide science, technology, and public policy guidance to private companies, philanthropies, and non-profit organizations. He is currently serving on the board of a number of corporations and non-profit organizations including the National Academy of Sciences board on research, data, and information. Mike was previously vice president of science and technology for the Laura and John Arnold Foundation who is responsible for identifying and pursuing opportunities for philanthropic investment in science and technology. Prior to this, he served as the assistant directors for Biotechnology in the Obama White House Office of Science and Technology Policy for seven years where he helped develop eight executive orders and other directives addressing issues ranging from the antibiotic resistance crisis to restoring pollinator health. He was also a former director of biology policy for the Federation of American Scientists where he led its Bio-security project. His public policy experience also includes working as a legislative fellow for US Senator Harry Reid, and as a public fellow for the National Human Genome Research Institute. Prior to his arrival in Washington, Mike worked as the senior editor at Nature Genetics. Mike earned his Ph.D. in genetics while working at Cold Spring Harbor Laboratory. He earned his degree in BS Biology at SUNY Stony Brook. What You’ll Hear On This Episode of When Science Speaks How Mike Stebbins got involved in public policy and his advice for scientists who would also like to be involved in policy-making Areas of science policy-making need skill strengthening and development Why PhDs and Postdocs need to view the transition into public policy as a new discipline Why persistence is a valuable asset in policy Mike’s major lessons from his time at the White House Employing the Tom Sawyer technique when driving people towards a goal The similarities of scientists and policy-makers How to get relationship-building right in the White House in order to get positive policy outcomes and how to make people passionate about executive actions How scientists can get people to listen to their findings in the realm of policy-making Mike’s example of how two factions with different opinions can work together   Connect with Mike Stebbins Mike Stebbins on LinkedIn Mike Stebbins on Twitter Mike Stebbins on Medium   Scientists in the world of policy-making Public policy is a tedious field of challenges where your rejections and failures become an essential part of getting the policies that you want to get implemented to function the way that you have envisioned in your mind. And the reason why a lot of scientists are coming into policy-making is because of the similarities between doing work in the laboratory and in drafting policy. The desire to get solutions for problems that once resolved could potentially make things better for everyone is the driving force for many of these special people to do their job and to do it extremely well. Mike Stebbins is a renowned geneticist who got involved in policy-making through his work in the White House and his legislative fellowship under US Senator Harry Reid, and as a public fellow for the National Human Genome Research Institute. His top notch advice for scientists who are rearing to enter the hectic and challenging world of policy-making is to view the field with a different perspective. It’s an entirely new field that relies heavily on building relations in order to get things done and knowing how to make different people come together towards a common cause is critical to the success of a certain policy. The value of bringing different people together in policy-making Mike Stebbins shares his first-hand experience in seeing how policy-making works through his experience working in the field. He has seen how people come together to get to an agreement that can effectively resolve an issue that would become an executive order that gets results such as when he developed executive orders and directives that addressed issues ranging from antibiotic resistance to restoring pollinator health. The key to getting the results he needed to see? Relationship-building. Getting people to become enthusiastic and passionate about the project that they are working on and getting them to share their expertise and skills to get to a point where all questions have been answered and resolved is crucial in policy-making. Banding people together for a cause greater than themselves and pushing aside other things that they may have invested in to get a policy off the ground is challenging and ultimately very rewarding. Policy-making is a selfless act bound by the desire to improve things and get things done. Learn more about Mike Stebbins and what he has learned from his time as a policymaker on this week’s episode of When Science Speaks. Connect With Mark and When Science Speaks http://WhenScienceSpeaks.com https://bayerstrategic.com/ On Twitter: https://twitter.com/BayerStrategic On Facebook: https://www.facebook.com/Bayer-Strategic-Consulting-206102993131329 On YouTube: http://bit.ly/BSConTV On LinkedIn: https://www.linkedin.com/in/markdanielbayer/ On Instagram: https://www.instagram.com/bayerstrategic/ On Medium: https://medium.com/@markbayer17    Subscribe to When Science Speaks on Apple Podcasts or Stitcher Bayer Strategic Consulting is a training and consulting firm that helps scientists and engineers effectively communicate the value of their work to their most important stakeholders using jargon-free and engaging language that gets results. Get a free consultation today to find out what they can do for you and your work.

This episode of the Free To Choose® Media Podcast features three prominent intellectuals in the field of neuroscience. Dr. Timothy Tully, former Senior Staff Investigator at the Cold Spring Harbor Laboratory, Dr. Eric Kandel, former Senior Investigator at the Howard Hughes Medical Institute and 2000 Nobel Prize winner in Physiology/Medicine, and Dr. Patricia Goldman-Rakic, Professor of Neuroscience at the Yale University School of Medicine. They discuss the results of their experiments on short- and long-term memory while discussing the history of our knowledge of the topic. Originally Recorded: 1993

Guests: Jiliian Capodice (Associate Professor at the Icon School of Medicine at Mount Sinai) and Charlie Prizzi (VP for Advancement, Special Adviser to the President at Cold Spring Harbor Laboratory) 

Our diet can play a huge role in how well, or not well, our bodies function. While we have an understanding of how our digestive tract processes food, there is a lot of ambiguity around what happens next. Dr. Semir Beyaz and his team at Cold Spring Harbor Laboratory aim to understand how what we eat affects us at physiological, cellular, and molecular levels. He joins us today to share some of his findings and future directions of his research. Listen in to hear more. Dr. Beyaz acknowledges that there are a lot of claims around nutrition that are not scientifically backed. He encourages you to seek out primary literature when doing your own research. He recommends the American Cancer Society, the Centers for Disease Control and Prevention (CDC), and FDA guidelines if you are interested in learning more about nutrition.  If you have questions about his research or would like more information, email him at beyaz@cshl.edu.

Dr. Molly Gale Hammell is an Associate Professor in Quantitative Biology at Cold Spring Harbor Laboratory. She sequences genomes and analyzes genome sequences to understand which differences in our genomes are due to random variation between individuals, and which are associated with diseases. In particular, she focuses on studying elements of the genome associated with neurodegenerative diseases like amyotrophic lateral sclerosis (ALS). In her free time, Molly loves gathering a group of friends together to attend some of the many fantastic live music concerts in the New York City area. Molly received her PhD in Physics and Astronomy from Dartmouth College. She then conducted postdoctoral research with Dr. Victor Ambros at the University of Massachusetts Medical School before joining the faculty at Cold Spring Harbor Laboratory. Molly was named a Rita Allen Foundation Scholar in 2014, and she was awarded the Ben Barres Early Career Award in 2018. In our interview Molly shares more about her life and science.

Dr. Michelle Heck is a Research Molecular Biologist with the U.S. Department of Agriculture (USDA) Agricultural Research Service (ARS), an Associate Professor at the Boyce Thompson Institute for Plant Research, as well as an Adjunct Professor in the school of Integrative Plant Science at Cornell University. Michelle studies interactions between the insects that infest plants, the pathogens that those insects can transmit, the diseases that can occur as a result, and new ways to control the spread of these diseases. Outside the lab, she loves spending time with her fantastic family, being a musician, watching her kids get interested in music, and cycling in scenic areas nearby. Michelle received her B.A. degree in biology from Boston University and her Ph.D. in biology from Watson School of Biological Sciences at Cold Spring Harbor Laboratory. She then conducted postdoctoral research at Cornell University. Michell has received numerous awards and honors throughout her career, including the 2014 USDA ARS Herbert L. Rothbart Outstanding Early Career Scientist of the Year Award and a Presidential Early Career Award for Scientists and Engineers (PECASE) Award in 2017. In our interview, Michelle shares more about her life and science.

Semir Beyaz Kimdir? Konuşmacımız Semir Beyaz'ın özgeçmişi İzmir Yüksek Teknoloji Enstitüsü (İYTE) 2009 Moleküler Biyoloji ve Genetik bölümü mezunu olan Beyaz, lisans eğitimindeki ilk yılından itibaren TÜBİTAK'ın araştırma projesi destek programı kapsamında laboratuvarda immünoloji alanında bilimsel araştırmalar yapmıştır. 2007 yılında İYTE'de yaptığı çalışmalarla Ulusal İmmünoloji kongresinde “Genç Araştırmacı” ödülünü almıştır. Lisans eğitiminin daha ilk yıllarından itibaren büyük araştırmalar yapan Dr. Beyaz, lisansın ardından Harvard Tıp Fakültesi'nde araştırmacı olmuştur ve burada doktoraya da kabul edilmiştir. Doktora çalışmalarının bir kısmını Harvard Tıp Fakültesi Kanser ve Kan Hastalıkları Merkezi'nde kan hücreleri, kök hücreler ve epigenetik üzerine, diğer kısmını ise Massachusetts Teknoloji Enstitüsü (MIT) Kanser Merkezi'nde beslenme, kök hücre ve kanser arasındaki ilişki üzerine yürüttü. Dr. Semir Beyaz son olarak Cold Spring Harbor Laboratory'de 2018 yılında kendi araştırma laboratuvarını kurdu. Dr. Semir Beyaz'ın Uluslararası Kök Hücre Araştırmaları Derneği Üstün Başarı Ödülü, Amerikan İmmünoloji Derneği Genç Araştırmacı Ödülü, Janeway Ödülü, Erken Kariyer Akademisyen Ödülü, Harvard İmmunoloji ve Jeffreymodell Ödülü gibi prestijli ödülleri bulunuyor. ----------------------------------------------------------------------------------------------- Kesişen Yollar Derneği, eğitim ve sosyal hizmet alanlarında Türkiye'ye yönelik çeşitli projeler geliştirmekte ve etkinlikler düzenlemektedir. Bu projeler ve etkinliklerdeki amacımız eğitimde fırsat eşitsizliğini azaltmak ve bunu yaparken de bambaşka dünyaları ve farklı hayat tarzlarını kesiştirmek, birbirimizden öğrenmek, esinlenmek ve birbirimize ilham kaynağı olmak. Her şeyin başı eğitim fakat biz bunun farklılıklara saygıyı, hoşgörüyü, empatiyi ve sosyal sorumluluk bilincini aşılayan bir eğitim olduğuna inanıyoruz. Bu inancı bizimle paylaşan ve bize destek olmak isteyen, etnik kökeni, inancı, siyasi görüşü, cinsiyeti, cinsel yönelimi ve yaşı ne olursa olsun herkesle ortak bir paydada buluşabileceğimize inanıyoruz.

This week I enter the ‘smelliverse,’ the dimension of odors, with Alexei Koulakov, a professor at Cold Spring Harbor Laboratory. Alexei uses machine learning to explore the least understood of our senses: the sense of smell. He’s working to unlock the mechanism by which we perceive odors and to classify millions of volatile molecules by their smell.

Prostate cancer is the most common cancer among men (after skin cancer), and while it can often be treated successfully, metastatic disease remains challenging. Lloyd Trotman, PhD—a former American Cancer Society grantee and Professor at Cold Spring Harbor Laboratory—is trying to change that. He and his team recently developed the first genetic mouse model for the treatment and analysis of metastatic prostate cancer. Now they are seeking to translate their findings into patients to “turn lethal prostate cancer into a curable disease.”* In this interview he talks about the challenges of metastatic prostate cancer, the exciting discoveries he and his team have made, and how his work is getting closer to patients. *https://www.cshl.edu/research/faculty-staff/lloyd-trotman/

New York native Toni Fabric returns from Chicago for care and treatment at the Northwell Health Cancer Institute. Director of Surgical Oncology Dr. Matthew Weiss and institute-associate Dr. David Tuveson of Cold Spring Harbor Laboratory and the Lustgarten Foundation discuss pancreas cancer, Toni's positive outcome, and the Northwell Health Cancer Institute's multi-disciplinary strategy against this all-too-common illness, including; chemotherapy, surgical intervention, support for physicians, and patient-participation in genetic research.

The Immune team turns to chickens, which have been important in understanding the immune system, to show that infection of mature B cells is not required for the pathogenesis of Marek's disease herpesvirus. Hosts: Vincent Racaniello, Stephanie Langel, and Cynthia Leifer Subscribe (free): iTunes, Google Podcasts. RSS, email Become a patron of Immune! Links for this episode Role of B cells in Marek's disease pathogenesis (PNAS) In ovo vaccination (YouTube) First chickens lacking B cells (PNAS) Letters read on Immune 16 Time stamps by Jolene. Thanks! Weekly Science Picks Steph - 7 Days Out Cindy - Watson PBS documentary and Cold Spring Harbor Laboratory response Vincent - Dads can donate mitochondrial DNA and Chicken puns

Yesterday, during his Senate confirmation hearing for the position of US attorney general, William Barr was asked by Senator Amy Klobuchar, “If you're confirmed, will the Justice Department jail reporters for doing their jobs?” Well, it is now being reported that American-born Marzieh Hashemi, also known as Melanie Franklin, most famous for anchoring news programs and presenting shows for Press TV, was detained upon her arrival at St. Louis Lambert International Airport in St. Louis, Missouri, on Sunday, according to her family and friends. She was transferred by the FBI to a detention facility in Washington, DC. US officials have so far refused to provide any reasons for her apprehension, either to her or her family. At the time of this program, the FBI has not replied to Sputnik News' request for a statement on charges and her status. What's going on here?According to reports, four Americans were among 15 people killed today in a suicide bombing in northern Syria that was claimed by the Islamic State. The attack targeted a restaurant in the northern city of Manbij, where American soldiers and others would sometimes stop to eat during their patrols of the area. What does this tell us about the realities on the ground and US policy in the region? The House of Representatives has passed a resolution rejecting white nationalism and white supremacy in the wake of Representative Steve King's remarks. On Capitol Hill yesterday, House lawmakers voted overwhelmingly, 421 to one, in favor of the resolution. King attempted to defend himself on the House floor before voting in favor of the resolution. In an interview with the New York Times, the Iowa Republican said, "White nationalist, white supremacist, western civilization - how did that language become offensive?" House Republican leadership has rebuked his comments and stripped him of his committee assignments. Senate Majority Leader Mitch McConnell has suggested King find a new line of work. How much does race inform our politics? Also, a Nobel Prize-winning scientist who helped discover the DNA double helix is losing a number of honorary titles because of his views on race. The Cold Spring Harbor Laboratory says it is stripping former Director, President and Chancellor James Watson of his honors after comments he made in a new PBS documentary, "American Masters: Decoding Watson." The 90-year-old had already been fired from the lab in 2007 for claiming that black people are less intelligent, comments he retracted and apologized for. In the new film, Watson says his opinions on race and intelligence haven't changed and that blacks on average are less intelligent than whites because of genetics. How much does race inform our social and biological studies? GUEST:Nisa Muhammad - Former Press TV Host of American Dream.Akbar Muhammad - International representative of the Nation of Islam.Jeff Mackler - National secretary for Socialist Action.Dr. Shantella Sherman - Historical researcher and technical writer, author of In Search of Purity: Popular Eugenics & Racial Uplift Among New Negroes 1915-1935 and publisher of Acumen Magazine.Joseph L. Graves Jr. - American scientist and the associate dean for research and professor of biological studies at the Joint School for Nanoscience and Nanoengineering, which is jointly administered by North Carolina Agricultural and Technical State University and UNC Greensboro.

Bill Horan and NCC Student Zac Turkel talk with Dr. Adrian Krainer from Cold Spring Harbor Laboratory. His lab studies the mechanisms of RNA splicing, ways in which they go awry in disease, and the means by which faulty splicing can be corrected. In particular, they study splicing in spinal muscular atrophy, a neuromuscular disease that is the leading genetic cause of death in infants. It was recently announced that Dr. Krainer will split one of the most lucrative awards in science — a 3 million dollar Breakthrough Prize — for his research leading to the medication to treat Spinal Muscular Atrophy.

La científica María Blasco dirige el Centro Nacional de Investigaciones Oncológicas (CNIO), donde asimismo es jefa del Grupo de Telómeros y Telomerasa. Obtuvo su doctorado en 1993 en el Centro de Biología Molecular Severo Ochoa bajo la dirección de Margarita Salas; ese mismo año se trasladó a Cold Spring Harbor Laboratory en Nueva York (EE. UU.), incorporándose al laboratorio dirigido por Carol W. Greiderl. En 1997 regresó a España para establecer su propio grupo de investigación en el Centro Nacional de Biotecnología del CSIC. En 2003 se incorporó al CNIO como directora del Programa de Oncología Molecular y, dos años más tarde, fue nombrada vicedirectora de Investigación Básica. En junio de 2011 fue nombrada directora del CNIO. El trabajo de Blasco se ha centrado en demostrar la importancia de los telómeros y de la telomerasa en el cáncer, así como en enfermedades relacionadas con el envejecimiento. Ha publicado más de 250 artículos científicos en las más destacadas revistas internacionales y nacionales como Cell, Nature, Science o Cancer Cell, y ha recibido numerosos reconocimientos como el Josef Steiner Cancer Research Award en 2003, la Medalla de Oro de EMBO (European Molecular Biology Organization) en 2004, el Premio Rey Jaime I en Investigación Básica en 2007, el Premio Körber de la Ciencia Europea 2008 y el Premio Nacional de Investigación en Biología Santiago Ramón y Cajal en 2010. En 2017 recibió la Distinción al Mérito Científico de la Generalitat Valenciana. Es doctora honoris causa por las universidades Carlos III de Madrid y de Alicante. El diálogo se complementará con la proyección de vídeos e imágenes relacionadas con la actividad de la invitada.Más información de este acto

Guest Host: Hugo Bettencourt "We face a dilemma in conveying the scientific process to the public, and even within academia: Real science doesn't fit the elements of effective storytelling." Dennis had been vocal on topics surrounding academia, science and pseudoscience on social media for several years. Thus, he readily volunteered to co-organize the March for Science in Lisbon, in 2017. He wants to disseminate the understanding of science, humanities and academia by the public, but also systemic changes within academia. In the first part of this episode he explains how he decided to found Science for Progress, and what our current goals are. The second part is about the image of scientists in the public. In Dennis' opinion, story telling in scientific reporting, science journalism, but also in pop culture, creates a distorted image of scientists. The dilemma is that good story telling that consumers enjoy, does not fit the reality of scientific research. background Dennis is a neuroscientist from Germany. After receiving a college degree in biology, he did a PhD in neuroscience at Bielefeld University in Germany. He then worked as a postdoctoral fellow at Cold Spring Harbor Laboratory, and in 2015 he moved to Portugal for a second postdoctoral fellowship at the Champalimaud Foundation in Lisbon. Throughout his career he conducted research on animal behavior and the underlying neural activity.

Barbara McClintock’s work on the genetics of corn won her a Nobel prize in 1983. Her research on jumping genes challenged the over-simplified picture of chromosomes and DNA that Watson and Crick’s discovery has all too often been used to support. During the half century that she worked at the Cold Spring Harbor Laboratory she became something of a living legend, a pioneer in a time when women weren’t expected to take much interest in science. In that story, she made a profound discovery that her male colleagues dismissed for years, leaving her out in the cold until they finally realized that it was true and granted her a belated Nobel Prize. Philip Ball tells the story of Barbara McLintock's life and work, from her early preference for sports, for solitude, and for intellectual life, that disturbed her parents, to her meticulous research on corn. In conversation with her recent biographer, Dr Nathaniel Comfort of Johns Hopkins University, he explores the facts and the fictions that grew up around her. Philip Ball talks about the legacy of her discovery of jumping genes with Professor Greg Hannon of the Cancer Research UK Institute at Cambridge University, who spent 25 years working in the McLintock Laboratory at Cold Spring Harbor. Picture Corn Cobs, Credit: Philippe Huguen/AFP/GettyImages)

In this episode, we are talking to Jackie Giovanniello, a Ph.D. student in Neuroscience at Cold Spring Harbor Laboratory in NY. She works on understanding how neural circuits are disrupted in autism. She is also the Co-Founder of the Women in Science & Engineering Initiative (WiSE) at CSHL. Learn how she got over challenges and succeeded in securing 30,000 dollars in funding with over 100 members. Jackie shares her struggles, strengths, and ideas to get more women to wear & retain the pristine white lab coats! Links: CSHL WISE www.500womenscientists.org Twitter: @CSHL_WISE

For nearly 200 years, China has looked to the west as the source of the most modern and cutting-edge technologies. From the Self-Strengthening Movement in the 19th century to the 13th Five-Year Plan (2016-2020) and Made in China 2025, Chinese leaders have consistently sought to foster homegrown technologies and scientific discovery that can compete on a global stage. In 2015, Dr. Tu Youyou became China’s first Nobel Laureate in science after her breakthrough in malaria treatments that has saved millions of lives. Yet China still has numerous technological challenges; from the lackluster performance of its chipmakers to protecting air quality. How has China’s uneven emergence as a technological player shaped the Sino-American relationship? Nancy Liu and Lawrence Sullivan, the authors of the Historical Dictionary of Science and Technology in Modern China, addressed this question in a discussion with National Committee President Stephen Orlins on November 8, 2017, in New York. Nancy Liu is the recipient of a Ph.D. in molecular and cellular pharmacology from Stony Brook State University. She is a cancer research scientist on the faculty of the College of Staten Island in the Department of Biology and the medical technology program. She previously worked at Cold Spring Harbor Laboratory and the Zuckerman Research Center, Memorial Sloan Kettering. With a Ph.D. in political science from the University of Michigan where he studied with Professors Richard Solomon, Michel Oksenberg, and Harriet Mills, Lawrence R. Sullivan is an emeritus professor, Adelphi University. He also taught at Wellesley College, Brown University, Miami University, Ohio, and the University of Michigan. The National Committee on U.S.-China Relations (www.ncuscr.org) is the leading nonprofit nonpartisan organization that encourages understanding of China and the United States among citizens of both countries.

Elég, ha annyit mondunk, hogy az e heti vendégünk egy jó humorú orvos, matematikus, de mindenekelőtt agykutató? Hangya Balázzsal az MTA-KOKI egyik kutatócsoportjának a vezetőjével beszélgettünk agyakról, rágcsálókról, döntéshozatalról és high-tech sufnituningról. 01’05” Még ezen a héten elmondhatjátok a véleményeteket ezen a kérdőíven: https://goo.gl/forms/dKIXcXrfIx7uJOgp2 Amit ezúton is köszönünk. 02’29” Az e heti vendégünk Hangya Balázs, a Magyar Tudományos Akadémia Kísérleti Orvostudományi Kutatóintézetében működő Lendület Rendszerneurobiológia Kutatócsoport vezetője. Mi az a rendszerneurobiológia (systems neuroscience)? És mitől új? Vagy mitől nem új? 04’35” Miért végezzünk Magyarországon alapkutatásokat? Miért ne hagyjuk ezt meg más, tehetősebb országoknak? 05’31” Azért az agykutatás és neurobiológia Magyarországon eléggé ott van! Miért is? 06’16” Hogy kerül egy orvos-matematikus egy agykutató csoportba PhD-zni? Aztán egy genfi parti után hogy jut el a Cold Spring Harbor Laboratory-ba kutatni? 11’18” A rágcsálókogníció tudománya. Mire lehet megtanítani egy patkányt? Miért bizonyultak jobb kísérletni alanynak rágcsálók, mint egy főemlősök? 15’37” Milyen sejtek vesznek részt a figyelemben? Mik azok a kolinerg sejtek és hogyan vizsgálják őket? 17’30” Az optogenetika rejtelmei közérthetően. 20’35” Milyen sejtek vesznek részt a(z asszociatív) tanulásban? A pavlovi és az operáns kondicionálás. 22’15” A sajtó és a kattintásvadász címek. (Itt jegyezzük meg, hogy mi egyeztettünk Balázzsal az adás címéről.) 24’00” Mi köze az egerek tanulásának az Alzheimer-kór leküzdéséhez? (Nem, az Alzheimer ellenszere még nincs meg.) Milyen egy Alzheimer-modell egér? Pre-klinikai és klinikai kutatások. 26’17” Hogy néz ki a kutatócsoport munkája? A high-tech sufnituning jelentősége. 32’20” Mennyit segít Balázsnak a matematikusi háttér az agykutatásban? 33’10” Hogyan hozunk döntéseket. Ráfér (már) a kahnemani elméletre a (felül)bírálat. (A Nobel-díjas Daniel Kahneman és Amos Tversky elméletére utaltunk.) Mennyire jó a bennünk élő statisztikus? Mennyire biztos magában az agyunk? A jeldetekciós elmélet (signal detection theory). 39’16” Kezdődjön a kvíz! 40’05” Első kérdés: Melyik FPS (first person shooter) videójátékot használták fel arra, hogy az egerek számára virtuális valóságot hozzanak létre? 42’35” Második kérdés: Melyik érzékszervünk végez Fourier-transzformációt? (Békésy György, Nobel-díjas kutatóra utalunk. Egyben azt is megbeszéljük, hogy tudjuk elkülöníteni az egyes hangszerek hangját.) 44’15” Harmadik kérdés: Melyik jármű sebességéhez áll legközelebb az ingerületvezetés? 45’29” Negyedik kérdés: Hány hatóanyagot engedélyeztek eddig Alzheimer-kór kezelésére? (A podcastben Morgantj Café Connection (CC 3.0) zenéjét használtuk fel.)

Cold Spring Harbor Laboratory's first fully-produced podcast series! Base Pairs ​tells​ stories that ​convey​ the power of genetic information — past and present. This pilot episode exemplifies the series, offering one story about the quirky history ​behind the field of genetics​, and another about how a ​scientist recently discovered a new​ disorder.

Today, our guest is Anne Churchland, Associate Professor at Cold Spring Harbor Laboratory. We'll be speaking with her about finding science by teaching kids math, the neural basis of multisensory decision making, and the benefits of lab blogging.

An-Dinh Nguyen interviews James Hicks of Cold Spring Harbor Laboratory on June 24, 2014. Dr. Hicks will be a speaker at the Single-Cell Sequencing conference, part of the Next-Generation Dx Summit, August 19-21 in Washington, DC. Topics include the advantages of single-cell genomic analysis for personalizing cancer therapies, one method for making single-cell sequencing more cost efficient, the relationship between tumor heterogeneity and drug response and more.

Kip Harry interviews Gholson Lyon of the Cold Spring Harbor Laboratory on September 13, 2013. Dr. Lyon will be speaking during the Clinical Exome Sequencing conference at the Clinical Genomics & Informatics Europe Conference & Expo on December 4-6, in Lisbon, Portugal. Topics include: • Biology and Targeting of Cancer through Exome Sequencing • Technical Steps for Exome Sequencing • Analyzing Exome Data • Implementing Exome Sequencing in a Clinical Lab • Comparing and Contrasting Exome vs. Whole Genome Sequencing • Exome Sequencing Survey of Cancers • Standardizing Library Prep and Intra-Patient Genomic Heterogeneity • Exome Sequencing for Candidate Gene Discovery with Clinical Samples

**MicrobeWorld app users, click the "e" symbol in the bottom right corner of this description to watch a bonus video version of this episode!** Vincent and Stanley meet with Waclaw Szybalski and John Kirby at Cold Spring Harbor Laboratory on the occasion of its designation as a Milestones in Microbiology site. They reminisce about how the well known laboratory has advanced the science and teaching of microbiology, and discuss John’s work on the soil dwelling, predatory myxobacteria. If you don't have the app, please visit www.microbeworld.org/app to get more information about downloading the app for your iOS or Android device. This video is also available for free at www.microbeworld.org in the TWiM section, epsiode #40.